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Signal transducer and activator of transcription 3 (STAT3) is activated in 
response to a variety of cytokines and growth factors, leading to rapid 
alterations in gene expression and far-reaching consequences for development, 
cell survival, homeostasis and tumorigenesis. Mice with conditional knockout 
of STAT3 in different tissues revealed distinct roles of STAT3 depending on 
the cell type and stimulus. Our lab previously reported that mice with targeted 
disruption of STAT3 in the bone marrow (BM) developed severe neutrophilia, 
suggesting that STAT3 might be a negative regulator for granulopoiesis. In 
this study, the underlying mechanism for the regulatory role of STAT3 in 
granulopoiesis and neutrophil homeostasis was investigated using the mouse 
model of BM-specific STAT3 knockout (STAT3-CFF). 
      STAT3-CFF mice exhibited progressive neutrophilia, and BM 
transplantation experiments revealed that the aberrant neutrophil expansion 
was originated from the cell autonomous defects in STAT3-deficient 
hematopoietic stem and progenitor cells (HSPCs). The role of STAT3 in 
granulopoiesis was then inspected at two different stages, namely early 
hematopoiesis and terminal granulopoiesis. During early hematopoiesis, a 
prominent expansion of granulocyte/macrophage progenitors (GMPs) was 
observed in STAT3-/- HSPCs, at the expense of common lymphoid progenitors 
(CLPs) and megakaryocyte/erythrocyte progenitors (MEPs), indicating a 
preferred commitment to the granulocyte/macrophage lineage in the absence 
of STAT3. Furthermore, the expression of major lineage determinate genes for 
CLP and MEP was significantly impaired in STAT3-/- HSPCs while key 
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driving factors for myeloid lineage remained unchanged. These data suggests 
that STAT3 plays an important role in promoting the lineage determinate 
genes that drives the specification to megakaryocyte/erythrocyte and lymphoid 
fates during early hematopoiesis.  
      In addition, the progressive expansion of BM granulocytes in STAT3-CFF 
mice was found accompanied by a downregulation of IRF8, a myeloid 
suppressor, in STAT3-/- BM immature granulocytes. Moreover, chromatin 
immunoprecipitation assay and luciferase reporter assay revealed that IRF8 
was a potential STAT3 target gene. These observations imply that a STAT3-
IRF8 axis may be critical for maintaining the BM granulocyte homeostasis 
during terminal granulopoiesis. Meanwhile, expression profile of a group of 
epigenetic factors was screened in STAT3-/- immature granulocytes, and 
SIRT6 was found to be a potential STAT3 target in terminally differentiated 
myeloid cells.  
      In conclusion, STAT3 regulates granulopoiesis and neutrophil homeostasis 
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1.1 STAT Family Proteins and STAT3 
1.1.1 STAT Family Proteins 
STAT proteins are named after their dual roles as signal transducer and 
activator of transcription. The STAT family proteins consist of Stat1, Stat2, 
Stat3, Stat4, Stat5a, Stat5b, and Stat6. Stat1, the first STAT family member, 
was discovered and purified in 1990 (Fu et al., 1990), and its dual function 
was characterized in response to interferon-α treatment (Schindler et al., 
1992a; Schindler et al., 1992b). Other STAT family proteins were 
subsequently identified, and all these transcription factors are latent proteins 
residing in the cytoplasm until they are activated by extracellular signaling 
proteins, mainly cytokines and growth factors, that bind to specific cell-
surface receptors. The activated STAT proteins accumulate in the nucleus and 
drive transcription of target genes. Response of STAT proteins to extracellular 
signaling occurs in minutes, resulting in rapid alteration in downstream gene 
expression and far-reaching consequences for development, cell survival, 
homeostasis and tumorigenesis (Levy and Darnell, 2002).  
      JAK-STAT pathway is one of the most well characterized pathways 
downstream of cytokines and growth factors (Figure 1) (Levy and Darnell, 
2002). Upon binding of cytokines/growth factors to their cognate receptors on 
the cell surface, ligand-bound receptors undergo dimerization and allow 
transphosphorylation and activation of receptor-associated Janus kinases 
(JAKs). Activated JAKs phosphorylate the intracellular domain of the receptor, 
and the phosphorylated receptor tails recruit STAT proteins through the Src-
homology 2 (SH2) domains, followed by phosphorylation of STAT proteins at 
their conserved C-terminal tyrosine residue by JAKs. Once phosphorylated 
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and activated, STAT proteins form homo- or hetero- dimmers via reciprocal 
binding between phosphorylated tyrosine residue and SH2 domain, translocate 
into the nucleus, and induce the transcription of downstream genes.  
 
 
Figure 1. 1 Canonical JAK-STAT pathway (This figure is from a review article by 
Levy and Darnell, 2002). Sequential tyrosine phosphorylations are triggered by 
cytokine–receptor interaction. Receptor dimerization upon ligand stimulation leads to 
transphosphorylation and activation of receptor associated Janus kinases (JAKs). This 
is followed by phosphorylation of receptor tails and the recruitment of the signal 
transducers and activators of transcription (STAT) proteins through their SH2 
domains. STAT protein is then phosphorylated at the conserved C-terminal tyrosine 
residue by JAK, and the activated STAT proteins undergo dimerization followed by 




1.1.2 STAT3 Signaling 
Stat3 is known to be activated by various members of the family of interleukin 
6 (IL-6)-type cytokines, such as IL-6, IL-11, leukemia inhibitory factor (LIF), 
oncostatin M (OSM), ciliary neurotrophic factor (CNTF) and cardiotrophin-
1(CT-1), through a common signal-transducing subunit, gp130, in 
combination with respective ligand-binding subunits (Kishimoto et al., 1995). 
In addition, granulocyte colony stimulating factor (G-CSF) and leptin, the 
receptors for which are both homologous to gp130, are also reported to 
activate Stat3. Moreover, Stat3 activation is induced in response to stimulation 
of several receptor tyrosine kinases, such as epidermal growth factor (EGF) 
and platelet-derived growth factor (PDGF), and by various members of the 
interferon (IFN) (IL-10, IFNγ, and IFNα) and IL-2 (IL-2, IL-11 and IL-15) 
families. Most of these receptor molecules harbor a common Stat3 docking 
motif (YxxQ) in their cytoplasmic domain, similar as gp130 (Stahl et al., 
1995).  
      Upon ligand stimulation, Stat3 is activated by tyrosine phosphorylation at 
a single site close to the carboxy-terminus (Y705) mediated by Janus kinase, 
most often Jak1 (Guschin et al., 1995). The tyrosine phosphorylation is the 
essential prerequisite for Stat3 dimerization, nuclear translocation and DNA 
binding. Stat3 can also be phosphorylated at a serine residue within the 
transactivation domain (S727) by several other kinases such as Erk1, Erk2, 
and p38, and the serine phosphorylation is thought to augment the signal 
transduction activity of Stat3 presumably through enhanced recruitment of 




1.1.3 Tissue-Specific Functions of STAT3 
The biological functions of STAT proteins were firstly studied in cell culture 
systems, and later on, their in vivo functions were further revealed by gene-
targeted removal strategy in mice. STAT1- and STAT2-deficient mice are 
defective in multiple IFN-mediated functions and show compromised innate 
immune response (Durbin et al., 1996; Meraz et al., 1996; Park et al., 2000). 
STAT4- and STAT6-deficient mice are impaired in IL-12- and IL-14- 
mediated signaling and exhibit defective T helper (Th) 1 and Th2 responses 
respectively (Kaplan et al., 1996a; Kaplan et al., 1996b). Loss of STAT5a 
impairs the development of mammary gland due to the unresponsiveness to 
prolactin, whereas STAT5b knockout mice suffer from growth retardation 
indicating its important role in growth hormone regulation (Liu et al., 1997; 
Teglund et al., 1998). 
      Unlike the knockout of other STAT genes, ablation of STAT3 leads to 
early embryonic lethality at embryonic day 6.5 to 7.5 (Takeda et al., 1997), 
because STAT3 is crucial for maintaining the pluripotency of embryonic stem 
cells in vivo (Do et al., 2013). Therefore, in order to investigate the function of 
STAT3 at later stages of embryogenesis and beyond, disruption of STAT3 in a 
tissue- or cell- specific manner utilizing Cre-loxP recombination system is 
desired. 
(a) STAT3 in skin 
STAT3 deletion in epidermal and follicular keratynocytes executed by keratin 
5 promoter-driven Cre led to impaired second and subsequent hair cycles, but 
did not affect skin morphogenesis (normal first hair cycle and hair follicles). 
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Furthermore, STAT3-deficiency in the skin resulted in retarded wound healing 
processes due to poor motility of keratinocytes in response to growth factor 
stimulation despite the normal proliferation rate (Sano et al., 1999). The data 
suggests that STAT3 is dispensable for skin morphogenesis, but it plays an 
important role in maintaining the structure of epidermis in postnatal life. 
(b) STAT3 in mammary gland 
The role of STAT3 in mammary gland was addressed by crossing the floxed-
STAT3 mice with mouse expressing Cre recombinase driven by the milk 
protein gene β-lactoglobulin (BLG) promoter. STAT3-deficient mammary 
tissue exhibits a significant decrease in apoptosis and a remarkable delay of 
mammary gland involution (Chapman et al., 1999). Involution is associated 
with an increased level of insulin-like growth factor-binding protein-5 
(IGFBP-5), which induces apoptosis by sequestering the survival signal, 
insulin-like growth factor-1 (IGF-1). However, upregulation of IGFBP-5 was 
found abolished in STAT3-deficient mammary cells, implying that STAT3 
activates mammary involution through IGFBP5. 
(c) STAT3 in liver 
IFN-inducible Mx-Cre is able to achieve up to 90% deletion of STAT3 in liver 
cells, resulting in significant impairment of acute-phase response (Alonzi et al., 
2001a). It is known that IL-6, one of the classic STAT3 activators, functions 
primarily to induce acute-phase response in liver during inflammation, 
therefore the phenotype of such mutant mice is expected. In addition, STAT3 
has been demonstrated to play a role in liver regeneration in a conditional 
STAT3 knockout mouse model using Transthyretin promoter-driven Cre 
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(Moh et al., 2007). The study showed that STAT3 is required for survival in 
the acute stage after 70% hepatectomy as well as in inflammatory reactions 
after hepatocyte necrosis. However, the hepatocytic STAT3 may have limited 
role in liver mass recovery although DNA synthesis is impaired. 
 (d) STAT3 in brain 
Targeted deletion of STAT3 in brain by BAL promoter-driven Cre results in 
perinatal lethality (Alonzi et al., 2001b). STAT3 was known to be crucial for 
the neurotrophic effects of CNTF and LIF in developing sensory neutrons in 
vitro, providing the explanation for the poor survival of STAT3-deficient 
neuron cells in vivo. Consistently, an independent work using neutrofilament 
light chain (NFL) promoter-driven Cre demonstrated a crucial pro-survival 
function of STAT3 in injured motor neurons (Schweizer et al., 2002). In 
addition to the prior knowledge that STAT3 is required for signaling of gp130-
dependent cytokines such as CNTF and LIF for the survival of neuron cells 
(Kishimoto et al., 1995), a recent work revealed novel dual functions of 
STAT3 in regulating the reactive astrocytes in the healing process after spinal 
cord injury, suggesting a potential approach for the treatment of central neuron 
system injury (Okada et al., 2006).  Intriguingly, disruption of neural STAT3 
by Nestin promoter-driven Cre displayed unique phenotypes of obesity, 
diabetes, infertility and thermal dysregulation, demonstrating a critical role of 
STAT3 in leptin-mediated regulation of neuroendocrine homeostasis (Gao et 
al., 2004). 
 (e) STAT3 in T cells 
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The function of STAT3 in T cells was firstly examined by specific ablation 
using LCK promoter-driven Cre. STAT3-deficient T cells could undergo 
normal development, but they displayed a severely impaired proliferation to 
IL-6 due to a defect in IL-6-mediated suppression of apoptosis (Takeda et al., 
1998). It is not surprising because IL-6-triggered Stat3 activation has been 
well studied in the in vitro system (Kishimoto et al., 1995). STAT3-deficient 
T cells also showed a reduced proliferative response to IL-2 stimulation, due 
to the absence of Stat3-mediated expression of IL-2 receptor, namely IL-
2Rα (Αkaishi et al., 1998).  Later on, the functions of STAT3 in peripheral 
specialized T cell subsets were also extensively investigated. STAT3 has been 
identified as a prerequisite for the differentiation of T helper 17 (Th17) cells 
from CD4+ T cells (Yang et al., 2007), and it plays an essential role in 
modulating the balance of Th17 and regulatory T (Treg) cells, which is critical 
for host immunity and the preservation of tolerance (Chaudhry et al., 2009; 
Durant et al., 2010). 
(f) STAT3 in myeloid cells 
Disruption of STAT3 in the myeloid lineage was directed by macrophage and 
neutrophil specific lysozyme (LYSM) promoter-driven Cre (Takeda et al., 
1999). The mutant mice were highly susceptible to endotoxin shock and 
demonstrated augmented production of inflammatory cytokines in response to 
lipopolysaccharides (LPS) (Takeda et al., 1999). Moreover, aging mutant mice 
developed enterocolitis. Takeda et al. suggested that the excessive Th1 
response to endotoxin in STAT3-deficient mice was due to the impaired 
signaling to anti-inflammatory IL-10 stimulation in STAT3-/- macrophages 
and neutrophils, implying STAT3 is critical for the myeloid cells to respond to 
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IL-10-mediated anti-inflammatory signaling for the prevention of excessive 
Th1 response and chronic inflammation. In addition, an independent group 
using IFN-inducible Mx promoter driving Cre to ablate STAT3 in 
hematopoietic progenitor and differentiated blood cells reported that the loss 
of STAT3 led to neutrophilia, which is characterized as a high number of 
neutrophil granulocytes in blood, and the STAT3-null bone marrow was 
hyper-responsive to G-CSF stimulation (Lee et al., 2002). It was commonly 
believed that STAT3 is an essential component for G-CSF-driven proliferation 
and granulopoiesis (McLemore et al., 2001). However, the conditional 
knockout model revealed an unexpected and contradictory role of STAT3, 
providing direct evidence for STAT3-independent granulopoiesis and 
demonstrating the negative regulatory role of STAT3 in regulating 
granulopoiesis (Lee et al., 2002).  
      Collectively, STAT3 has been demonstrated to be activated by a variety of 
cytokines and growth factors, and plays critical roles in many aspects of 
physiological processes. The biological readout can be cell proliferation, 
survival, or apoptosis depending on the specific type of tissue as well as the 
particular context. The diverse but specific role of STAT3 is achieved through 
the activation of different subsets of downstream target genes in a tissue- and 
stimulus-specific manner, by interacting with specific partners/co-factors 
(either activators or suppressors), cross-talking with different signaling 
pathways, and possibly being fine-tuned the strength and duration of signaling 
via various suppressive feedback mechanisms. So far, many of the underlying 
mechanisms for the tissue-specific functions of STAT3 are not fully 
understood, yet to be further elucidated. It is important to understand the 
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molecular mechanism of Stat3 functions in different tissues, as it may shed 
light on pharmacological intervention of certain diseases caused by aberrant 
Stat3 functions (Holland et al., 2007).  
 
1.2 Hematopoiesis and Granulopoiesis 
1.2.1 Hierarchy of Hematopoiesis 
Mammalian hematopoiesis follows an orchestrated program of cell 
proliferation, differentiation, and apoptosis, resulting in the expansion of 
hematopoietic progenitor cells that are progressively restricted to distinct cell 
fates such as erythrocytes, leukocytes and thrombocytes. The erythrocytes, 
commonly known as red blood cells (RBCs), serve as vehicles for the 
transportation of oxygen and other nutrients. The leukocytes, or white blood 
cells (WBCs), including granulocytes (neutrophils, eosinophils and basophils), 
monocytes, and lymphocytes (B and T cells), on the other hand, are part of the 
immune system which helps our bodies fight against infections. Thrombocytes, 
also named platelets, play a key role in blood clotting at the damaged blood 
vessels to stop bleeding.  
      It is commonly agreed that the sequential differentiation of hematopoietic 
stem cells (HSCs) through progenitors to fully differentiated blood cells is a 
primarily irreversible process under normal physiological steady-state 
conditions. HSCs are tissue-specific stem cells that reside at the top of the 
hematopoietic hierarchy and give rise to committed progenitor cells and 
terminally differentiated effector cells through successive differentiation 
(Figure 1.2) (Bryder et al., 2006). HSCs, like other tissue-specific stem cells, 
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have the ability to self-perpetuate though a process known as self-renewal, and 
they have the potential to differentiate to all kinds of blood cells in a sustained 
manner. There are two sub-types of HSCs, the long-term HSC (LT-HSC) 
which is quiescent and short-term HSC (ST-HSC) which is active in self-
renewal and differentiation. The immediate progeny of HSCs are multipotent 
progenitor (MPP) cells that retain full lineage potential yet have a limited 
ability of self-renewal. MPP cells in turn give rise to oligo-potent progenitors, 
which possess more restricted differentiation potential. This is a branching 
point in the hematopoietic hierarchy with more lineage-restricted progenitors. 
The common lymphoid progenitor (CLP) is capable of giving rise to mature 
lymphoid effector cells including B, T, and natural killer (NK) cells but lacks 
the potential to form myeloid cells (Kondo et al., 1997). In contrast, common 
myeloid progenitor (CMP) gives rise to granulocyte/macrophage progenitor 
(GMP) which is capable of differentiating into monocytes/macrophages and 
granulocytes, and megakaryocyte/erythrocyte progenitor (MEP) which 
differentiates into megakaryocytes/platelets and erythrocytes, lacking the 
potential to form lymphoid progeny (Akashi et al., 2000). Interestingly, both 
CLP and CMP have been proposed to give rise to dendritic cells (Akashi et al., 







Figure 1.2 Hierarchy of hematopoiesis. (This figure is from Bryder et al. (2006)) 
Self-renewing hematopoietic stem cell (HSC) resides at the top of the hierarchy, 
giving rise to a number of multipotent progenitors which in turn differentiate to oligo-
potent progenitors including the common lympohoid progenitor (CLP), which gives 
rise to mature B lymphocytes, T lymphocytes, and natural killer (NK) cells, common 
myeloid progenitor (CMP) that gives rise to granulocyte-macrophage progenitor 
(GMP) and megakaryocyte/erythrocyte progenitor (MEP), the former one 
differentiates into monocytes/macrophages and granulocytes, and the latter one 
differentiates into megakaryocytes/platelets and erythrocytes. The cell surface 
phenotype of HSC and most progenitors for both murine and human systems is 




      It should be noted that Figure 1.2 only presents a simplified model of 
hematopoietic hierarchy, but it is not the full picture of hematopoiesis. First, 
the differentiation of lineage-restricted progenitors to mature blood cells 
proceeds through a number of intermediate stages, which are not illustrated in 
the diagram. Second, the lineage potential and developmental relationship of 
some of the hematopoietic subsets have not been fully resolved. For example, 
recent studies identified a new subtype of progenitors, named lymphoid-
primed multipotent progenitor (LMPP), that exhibits the combined lympho-
myeloid differentiation potential but fails to give rise to megakaryocyte and 
erythrocyte lineages, suggesting that LMPP is the precursor of CMP and CLP, 
such that MEP may originate from a multipotent progenitor and bypass the 
CMP intermediate (Adolfsson et al., 2005). Moreover and most importantly, 
the topic of hematopoiesis, although under extensive investigation, is still not 
fully understood by far, with lot of questions under debate and to be addressed. 
Hence, the model of hematopoiesis is subject to continuous modification as 
our knowledge grows. 
      There are several advantages in such multitiered differentiation scheme of 
hematopoietic process. Firstly, the proliferative potential of multi-potent, 
oligo-potent and certain types of effector cells reduces the proliferative 
pressure on HSCs themselves. The quiescence of LT-HSCs is critical for 
protecting the cells from potentially mutagenic hazards of DNA replication, 
cell division and high metabolic activities, maintaining the integrity and 
longevity of these cells (Rossi et al., 2005). Secondly, hierarchical 
differentiation scheme allows modulation of each specific lineage to suit the 
demand under different physiological and pathological conditions. For 
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instance, GMP, which gives rise to mature granulocytes that turn over very 
rapidly have a very high proliferative index, whereas CLP has a much lower 
proliferative index (Passegué et al., 2005), presumably due to the fact that the 
progeny of the CLP are more long-lived B and T cells which themselves are 
capable of proliferation during maturation. Furthermore, a rapid increase in the 
production of neutrophils is the primary response to infection (Al-Gwaiz and 
Babay, 2007), demonstrating that hematopoiesis is able to be fine-tuned to 
meet the demand of a particular effector cell type. 
      Hematopoiesis generally refers to the hematopoietic process occurring in 
the bone marrow, which is the major hematopoietic site after birth. 
Hematopoiesis occurring in the organs outside of the bone marrow is defined 
as extramedullary hematopoiesis (EH). EH takes place in diverse conditions, 
including fetal development, normal immune responses, and pathological 
circumstances (Kim, 2010). During fetal development, EH occurs in the yolk 
sac, fetal liver and spleen before the formation of bone marrow. In adults, EH 
can be activated in peripheral organs such as spleen and liver during immune 
responses following infection. EH also occurs in liver and spleen as a result of 
failed marrow hematopoiesis, and it is considered as a passive form of EH. 
Under all circumstances, EH is able to produce all types of blood cells for the 





1.2.2 Flow-cytometry Based Characterization of Hematopoietic Stem and 
Progenitor Cells 
A single HSC undergoes a series of differentiation processes to give rise to 
terminally differentiated cells, passing through a number of intermediates in 
the hierarchy. Hence, in order to study the cellular and molecular processes 
during hematopoiesis, it is important to purify the appropriate lineage at the 
defined developmental stage. Previous studies have demonstrated that certain 
combinatorial expression patterns of cell surface proteins in hematopoietic 
progenitors are associated with functional distinct cellular properties, which 
suggests a good approach to identify the cells without disrupting them. With 
the advanced technology, flow cytometry nowadays has been routinely 
employed to simultaneously assess multiple protein markers on the cell 
surface for cell type characterization.  
      Twenty years ago, Okata et al. discovered that lineage-negative, Sca-1-
positive, and c-kit-positive fraction (LSK) from murine bone marrow cells 
were capable of reconstituting all the blood lineages in lethally irradiated 
recipients (Okada et al., 1992), implying the multipotent HSCs reside within 
this minor LSK fraction in the bone marrow. However, although LSK cells are 
enriched for HSC activity compared to whole bone marrow (~1000 fold), the 
majority of LSK cells are multipotent progenitors and only 1/30 of LSK cells 
are the actual stem cells capable of long-term multi-lineage repopulation 
(Bryder et al., 2006). Due to the heterogeneity of LSK cells, additional cell 
surface markers are introduced to define the subtypes of early hematopoietic 
progenitors in mice (Figure 1.2). CD34 and Flt3 (also known as flk2 or CD135) 
are commonly used to differentiate long-term HSC, short-term HSC and MPPs 
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within the LSK population (Christensen and Weissman, 2001; Osawa et al., 
1996),  while other groups adopt another set of surface markers including 
Thy1.1, CD105 (Endoglin) and CD150 (Slamf1) to assess the stemness (Chen 
et al., 2002; Kiel et al., 2005b; Spangrude et al., 1988). In order to determine 
the HSCs and various progenitors more precisely, researchers are trying to 
include as many markers as possible depending on the capability of 
fluorescence detection in the flow cytometer.  
      Although tremendous work has been done in mice to resolve the 
combinatorial expression of surface markers on different subsets of HSCs and 
MPPs, unfortunately it applies to the human system to a very minimal extent 
(Figure 1.2). For instance, murine HSCs are characterized as a CD34- 
subgroup of LSK, whereas majority of human HSCs are CD34+. Thus, human 
HSCs and lineage-restricted progenitors acquire a distinct set of combinatorial 
surface markers (Novershtern et al., 2011). For example, CD38 and CD90, 
which are not used for HSC determination in mouse, are employed for 
identifying human HSCs. In addition, to differentiate CMP, GMP and MEP, a 
combination of CD38, CD123 (IL3Ra) and CD45Ra is employed in human, 
instead of the combination of cKit, Sca-1, CD34, CD16/32 (FcγR) in mouse. 
The combinatorial surface markers for identifying the subsets of human MPPs, 
however, have not developed and remain to be further elucidated. 
 
1.2.3 Cellular and Molecular Regulators in Hematopoiesis 
Due to the short life span of most terminally differentiated blood cells, 
generation of mature blood cells is an ongoing process which generates more 
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than 4 million blood cells every second in an adult human (Borregaard, 2010). 
The enormous amplification in the numbers of differentiated blood cells from 
a small group of HSCs requires precise control at multiple stages. 
      Lifelong production of blood cells is achieved by the ability of HSCs to 
differentiate and self-renew, which establish the primary level of homeostatic 
control within the hematopoietic system. HSCs are found to reside in a 
specific microenvironment known as the stem cell niche. Recent studies in 
adult bone marrow identified osteoblast and endothelial cells as two important 
supportive cell types within the niche (Calvi et al., 2003; Kiel et al., 2005a). It 
was demonstrated that interaction of HSCs with the cellular and extracellular 
components within the endosteal and perivascular regions are critical for the 
regulation of HSCs, in the aspects of self-renewal, quiescence and 
mobilization (Arai and Suda, 2007; Nilsson et al., 2005; Oh and Kwon, 2010).   
      For years, researchers have been trying to figure out the molecular 
mechanisms underlying the fate decision in HSCs. Recently, with the 
advances of modern technology, unique expression patterns associated with 
lineage commitment have been identified in mouse and human by using the 
high-throughput microarrays (Novershtern et al., 2011; Terskikh et al., 2003). 
One of the surprising findings from the genome-wide screening is that HSCs 
express a great variety of genes that were originally believed to be restricted to 
more mature and lineage-committed cell types, and a lot of overlaps in the 
expression profiles are found in cells at various differentiation stages and of 
different lineages. Meanwhile, a group of genes are shown to be lineage-
restricted, and many of which has been reported to play critical roles in fate 
determination by earlier studies using the conventional polymerase chain 
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reaction strategies (Hu et al., 1997; Miyamoto et al., 2002). Among these 
lineage-associated genes, some are necessary to prime the primitive progenitor 
cells for differentiation toward specific lineages, acting as master regulators 
for lineage specification. For example, disruption of transcription factors PU.1 
and GATA-1 in lineage-restricted progenitors is sufficient to abolish the 
lineage commitment to myeloid cells and erythrocytes respectively (Kitajima 
et al., 2006; Scott et al., 1994). Moreover, lymphoid specification in the bone 
marrow, especially the early B cell development is determined by a network of 
transcription factors E2A, EBF and Pax5, and loss of either one fails to 
generate B lineage lymphocytes in vivo (Bain et al., 1994; Lin and Grosschedl, 
1995; Mikkola et al., 2002). Interestingly, some lineage determinate genes are 
even potent to switch the cell fate from a committed cell type to another 
lineage. It was reported that GATA-1 could convert lymphoid and 
myelomonocytic progenitors into the megakaryocyte/erythrocyte lineage 
(Iwasaki et al., 2003),  and similarly PU.1 and CCAAT/enhancer binding 
protein (C/EBP) family members C/EBPα/β are able to reprogram the 
lymphoid lineage into myeloid fate (Laiosa et al., 2006; Xie et al., 2004). All 
these studies suggest that cell fate is determined by a combinatorial expression 
patterns with a few driving transcription factors for lineage specification. 
      In addition to the transcription factors, modulation of gene expression by 
chromatin modification which is termed as ‘epigenetic’ regulation (changes in 
gene expression without alteration in DNA sequences) has been proposed to 
play a critical role in hematopoiesis and other biological activities (Rando and 
Chang, 2012; Surani et al., 2007). Epigenetic modifications, including DNA 
methylation and nucleosomal histone tail modifications such as acetylation, 
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methylation, phosphorylation, SUMOylation and ubiquitylation, collectively 
constitute the ‘histone code’ and are capable of affecting the chromatin 
structure and gene transcription. For example, the specific expression of PU.1 
(coded by SPI1) in HSCs, myeloid cells, and differentiated B cells, but not T 
cells, correlates with the methylation status of the SPI1 5’-UTR, which is 
hypermethylated in T cells (Ivascu et al., 2007). The epigenetic modifications 
on the histone tails are catalyzed by opposing families of enzymes, such as 
histone acetyltransferases (DACs)/histone deacetylases (HDACs), histone 
methyltransferases (HMTs)/histone demethylases (HDMs), and DNA 
methyltransferases (DNMTs), which are also termed ‘epigenetic factors’. It is 
generally believed that these epigenetic factors work in concert with lineage-
restricted transcription factors to regulate the lineage commitment decisions 
during hematopoiesis. For instance, GATA1 recruits HAT-containing 
complexes to β-globin gene locus resulting in acetylation of histone H3 and 
H4 so as to stimulation transcription activation of β-globin during 
erythropoiesis (Letting et al., 2003). It is also reported that during myeloid 
differentiation, PU.1 recruits HMTSuv39h1, and retinoblastoma (Rb) protein 
to the GATA-1target genes to antagonize the transcription activity of GATA-1, 
thereby inhibiting the differentiation to erythroid lineage (Stopka et al., 2005). 
Moreover, mice deficient in enhancer of zeste protein-2 (EZH2) which 
specifically methylates H3K27 and H1K26 exhibit impaired B cell 
development primarily caused by decreased rearrangement of the 
immunoglobulin heavy chain (Su et al., 2003). These findings demonstrate the 
potential of one single epigenetic factor in regulating the critical biological 
activities. A lot of studies have been done to address the epigenetic regulatory 
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mechanisms in normal and malignant hematopoiesis in the past decade, and it 
may bring potential therapeutic benefits in future (Rice et al., 2007).  
 
1.2.4 Hierarchy of Granulopoiesis 
Granulocytes are the most abundant type of myeloid cells in the blood stream, 
and play essential roles in the innate immune system as a front line defense 
against bacterial and fungal pathogens. Granulocytes are characterized by two 
morphological features: the multilobulated shape of the nucleus and the 
eponymous, excessive enrichment of the storage vesicles, named granules, in 
the cytoplasm. Based on the staining properties of these granules, the 
granulocytes can be further subdivided into neutrophils, eosinophils and 
basophils. The most frequent granulocytes are neutrophils that are constantly 
generated in a high number in the bone marrow, and circulate in the blood 
stream until activation in response to infections. Eosinophils are mainly 
responsible for combating the multicellular parasites, and the least common 
basophils are one of the major sources of histamine in allergic reaction. 
      The process of production of granulocytes from hematopoietic 
stem/progenitor cells in the bone marrow is termed as granulopoiesis, or 
granulocytopoiesis. Although different types of granulocytes have distinct 
immune functions, the differentiation pathways of neutrophils, eosinophils and 
basophils share huge similarities. They all arise from the same differentiation 
process from HSC through a serious of progenitors until the GMP stage. GMP 
gives rise to eosinophil lineage-committed progenitor (EoP) (Iwasaki et al., 
2005) and basophil/mast cell progenitor (BMCP) that in turn derives mast cell 
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progenitor (MCP) and basophil progenitor (BaP) (Arinobu et al., 2005), yet 
the committed progenitor of neutrophils is not described (Figure 1.3).  
         
Figure 1.3 Hierarchy of granulopoiesis. (This figure is from a review article by 
Fiddler and Brunner (Fiedler and Brunner, 2012)) HSC, hematopoietic stem cell; 
MPP, multipotent progenitor; CMP, common myeloid progenitor; GMP, 
granulocyte/macrophage progenitor; MDP, monocyte/dendritic progenitor; BMCP, 
basophil/mast cell progenitor; MCP, mast cell progenitor; BaP, basophil progenitor; 
EoP, eosinophil progenitor; NP, neutrophil progenitor (putative). 
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      As neutrophilic granulocytes are the predominant population and account 
for over 90% of granulocytes, granulopoiesis in this thesis refers to the 
differentiation of neutrophils, unless specified otherwise. Terminal 
granulopoiesis starts with the myeloblast and promyelocyte state, where the 
switch from proliferation to differentiation takes place, as well as the 
formation of the first granule starts (Figure 1.4) (Borregaard, 2010) The 
myeloblasts still possess proliferative potential, which is lost in promyelocytes 
and onwards. Meanwhile, segmentation of nucleus and a sequential formation 
of different types of granules start since the myeloblast/promyelocyte stage 
until the cell finally differentiates into a mature neutrophil (Borregaard and 




Figure 1.4 Terminal granulopoiesis in the bone marrow. (This figure is from a 
review article by Borregaard (2010)) Terminal granulopoiesis is characterized by 
segmentation of the nucleus and sequential formation of different subtypes of 
granules: azurophil (red), specific granules (green), gelatinase granules (yellow) and 
secretory vesicles (empty). During terminal granulopoiesis, the transcription factors 
expression differentially at different stages, which is critical for the regulation of 




1.2.5 Homeostatic Regulation of Neutrophil Count 
      To maintain the appropriate neutrophil counts, the process of 
granulopoiesis is tightly regulated. In the steady state, bone marrow 
continuously produces granulocytes and stores a reservoir of immature and 
mature neutrophils, while circulating neutrophils have a short life span of 5-7 
days, and the number is maintained within a narrow range (3.5-4.5 x 106/ml 
for humans and approximately 4.9 x 105/ml for mice) (von Vietinghoff and 
Ley, 2008). The neutrophil production is responsive to environmental stresses 
such as infection, which accelerates the process of granulopoiesis, enhances 
both neutrophil production in the bone marrow and neutrophil migration from 
bone marrow to peripheral blood. This response, termed as ‘emergency’ or 
demand-driven granulopoiesis, is characterized by enhanced cell cycle 
progression of granulocyte precursors and efflux of mature neutrophils from 
the bone marrow, relative to the steady state conditions. Granulocyte colony-
stimulating factor (G-CSF) is believed to be the mediator of emergency 
granulopoiesis, and its serum level increases 10-20 fold during infection, and 
it has long been used therapeutically to boost the neutrophil counts in the 
immunosuppressive patients (Lord et al., 1989).  
      Granulopoiesis is boosted during infections, and the neutrophil 
homeostasis has to be restored when the infection is eradicated. Hence, 
appropriate apoptosis of circulating neutrophils is critical for neutrophil 
homeostasis. Defective apoptosis of peripheral neutrophils has been shown to 
promote inflammation and autoimmune diseases (Gabillet et al., 2012; 
Midgley et al., 2009). Thus, apoptosis of neutrophils should be precisely 
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controlled in order to maintain a balance between effective immunity versus 
immunosuppression or autoimmune disease.  
      Furthermore, granulopoiesis in the bone marrow is tightly regulated by the 
rate of apoptosis of neutrophils in the tissues through feedback systems. It has 
been shown that macrophages and dendritic cells secret less IL-23 when they 
phagocytose apoptotic neutrophils, resulting in reduced IL-17 production by 
regulatory T cells and subsequent lower level of G-CSF in the serum, as IL-17 
is an important stimulus for G-CSF production (Stark et al., 2005; von 
Vietinghoff and Ley, 2008). These studies suggest that G-CSF-mediated 
granulopoiesis is modulated by the phagocytosis of neutrophils via cytokines 
such as IL-17 and IL-23. 
      Neutrophilia and neutropenia are observed when the homeostatic condition 
of neutrophil regulation is disrupted, which are characterized by abnormally 
high and low count of circulating neutrophils respectively. Neutrophilia could 
be a normal physiological response to infection and inflammation, as a result 
of stimulated emergency granulopoiesis, and the homeostasis will restore once 
the infection or inflammation is cleared. Neutropenia, on the contrary, is a 
hematological disorder. Patients with neutropenia are very susceptible to 
frequent or severe infections. Animal models lacking G-CSF or G-CSFR (G-
CSF receptor) develop severe neutropenia (Lieschke et al., 1994; Liu et al., 
1996), demonstrating the crucial role of G-CSF signaling in homeostatic 
granulopoiesis. Currently there is no ideal therapy for neutropenia, but 
recombinant G-CSF is effective to boost granulopoiesis in patients with 
congenital neutropenia and in patients under chemotherapy.  
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1.2.6 Transcription Factors in Granulopoiesis 
PU.1 and C/EBPα are not only required for initial myeloid lineage 
commitment as described earlier (Laiosa et al., 2006; Scott et al., 1994), but 
also essential for terminal granulopoiesis. Once the hematopoietic progenitors 
are committed to myeloid fate, subsequent decision between granulocyte and 
monocyte specification is determined by the balance between PU.1 and 
C/EBPα: high expression of PU.1 drives monocytic differentiation, whereas 
C/EBPα is required for granulopoiesis (Dahl et al., 2003; Laslo et al., 2006). 
However, C/EBPα was suggested dispensable for granulopoiesis as it was 
demonstrated that granulopoiesis in C/EBPα-deficient mice could be rescued 
by C/EBPβ with stimulation of IL-3 and granulocyte-monocyte colony 
stimulating factor (GM-CSF) (Hirai et al., 2006). Moreover, C/EBPβ plays an 
essential role for accelerating granulopoiesis in response to fungal infection 
(Hirai et al., 2006). C/EBPε, on the other hand, is required for the transcription 
of granule proteins at the myelocyte stage and beyond (Yamanaka et al., 1997), 
suggesting its critical role in terminal differentiation and maturation of 
granulocytes. In addition, growth factor independent-1 (GFI-1) is reported as 
an essential transcription factor in neutrophil differentiation, as mice deficient 
of GFI-1 suffer severe neutropenia (Karsunky et al., 2002). Further 
investigation revealed that GFI-1 is upregulated during stem cell commitment 
to the myeloid lineage and it drives towards granulocyte development by 
suppressing monocyte-specific genes, like macrophage-colony stimulating 
factor (M-CSF) and M-CSF receptor (M-CSFR) (Zarebski et al., 2008).  
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      Gene-targeting approaches also revealed a number of genes that are 
involved in the modulation of granulopoiesis. For example, loss of the 
transcription factors such as IRF8, STAT3 or JunB/AP1 in myeloid lineage 
induces excessive production of granulocytes (Holtschke et al., 1996; Lee et 
al., 2002; Santaguida et al., 2009), suggesting that they are potential negative 
regulators for granulopoiesis. 
 
1.3 STAT3 and Granulopoiesis 
1.3.1 Role of STAT3 in Granulopoiesis 
The signaling transduction pathways that regulate granulopoiesis are of great 
interest. G-CSF signaling is most extensively studied as it has been shown to 
specifically stimulate the commitment of hematopoietic progenitor cells to the 
myeloid lineage. Early work using G-CSF responsive cell lines demonstrated 
potent activation of STAT3 as well as weak activation of STAT1 and STAT5 
upon G-CSF stimulation, and STAT3 activation was required to promote 
cytokine-mediated proliferation (Tidow and Welte, 1997). STAT3 activation 
was implicated in arrest of granulopoiesis and terminal differentiation by 
another group (Coffer et al., 2000), probably due to the cell type-specific 
variations among cell lines. Later on, it was reported that ablation of the 
STAT3 recruitment site on the G-CSF receptor or ectopic expression of 
dominant negative (DN)-STAT3 led to neutropenic phenotype, similar to G-
CSF- and G-CSFR-deficient mice, suggesting STAT3 is a major mediator for 
G-CSFR signaling (McLemore et al., 2001). The precise role of STAT3 in 
granulopoiesis was not elucidated until transgenic mice with targeted STAT3 
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disruption were generated. Surprisingly, mice lacking STAT3 in the whole 
bone marrow or specifically in the myeloid lineage developed severe 
neutrophilia, a syndrome of excess circulating neutrophils, suggesting that 
STAT3 is a negative regulator for granulopoiesis (Lee et al., 2002; Takeda et 
al., 1999). In addition, deletion of STAT3 during hematopoiesis caused overly 
pseudoactivated innate immune responses, leading to inflammatory bowel 
disease (IBD) in both small and large interstine with segmental inflammatory 
cell infiltration, ulceration, bowel wall thickening and granuloma formation 
(Takeda et al., 1999). Our lab previously engineered a transgenic mouse with 
tissue-specific ablation of STAT3 in bone marrow driven by TIE2 promoter 
directed Cre, and we reported such transgenic mice exhibited neutrophilia 
(Welte et al., 2003). This is consistent with previous in vivo findings that 
STAT3 plays a suppressive role in granulopoiesis. Moreover, STAT3 deletion 
in the bone marrow caused Crohn’s disease-like pathogenesis and early 
lethality (within 4-6 weeks after birth), while STAT3 deletion in the 
committed myeloid cells driven by LysM promoter-Cre displayed relatively 
late onset of enterocolitis and death (age of 20-24 weeks) (Takeda et al., 1999). 
All the observations from various conditional STAT3 knockout mice 
collectively suggest that STAT3 plays a negative role in granulopoiesis and it 
is important for immune tolerance in the intestine. STAT3 deletion in myeloid 
lineage is sufficient to cause neutrophilia and IBD, and the absence of STAT3 





1.3.2 Contradictory and Unaddressed Questions 
Although targeted disruption of STAT3 in the hematopoietic tissue has 
demonstrated a suppressive role of STAT3 in granulopoiesis, there are still 
many questions remain to be addressed. 
      Firstly, detailed examination of granulopoiesis in STAT3 BM-targeted 
mice involving the frequency of HSCs and a series of progenitors in early 
hematopoiesis has not been performed, and little is known about the role of 
STAT3 in early hematopoiesis. A recently study reported STAT3 deficiency 
in HSPCs led to mitochondrial dysregulation, resulting in excessive ROS 
production and defects in cell function (Mantel et al., 2012). However, why 
STAT3 deficiency results in preferred myelopoiesis and neutrophil 
development is still elusive. Hence, possible role of STAT3 in regulating 
lineage determination needs to be addressed.  
      Secondly, the molecular mechanisms underlying the repressive role of 
STAT3 in granulopoiesis have not been fully elucidated. When cultured in 
vitro, STAT3-deficient bone marrow cells exhibit significantly increased 
autonomous proliferation of neutrophils (Welte et al., 2003), suggesting that 
over-activated granulopoiesis is due to inherited defects in hematopoietic 
progenitor cells and neutrophils. One group proposed that STAT3 directs a 
negative feedback loop of granulopoiesis through induced expression of its 
downstream target, suppressor of cytokine signaling 3 (SOCS3) (Lee et al., 
2002). Lack of SOCS3 in the absence of STAT3 allows prolonged activation 
of extracellular regulated kinase (ERK) signaling and subsequently enhances 
cell proliferation (Kamezaki et al., 2005). However, the compromised level of 
SOCS3 in the absence of STAT3 is not sufficient to explain the hyper-
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proliferative phenotype specifically in neutrophil granulocytes but not 
lymphocytes or other cell types. Another group suggested the expansion of 
neutrophils was caused by the impaired response in STAT3-/- immune cells to 
the anti-inflammatory cytokine interleukin 10 (IL-10) that suppresses Th1 
response (Takeda et al., 1999). It seems that STAT3 plays different roles in 
neutrophil production and function in bone marrow and in periphery, 
suggesting distinct pathways of STAT3 signaling accounting for the 
homeostasis of neutrophils at different stages of neutrophil development, 
which requests further investigation. 
      In addition, the understanding of the interaction or cross-talk of STAT3 
with other granulopoiesis-regulatory genes is still a tip of iceberg. C/EBP 
family proteins and PU.1 has been shown to be essential transcription factors 
necessary for steady-state granulopoiesis and emergency granulopoiesis. 
STAT3 has been demonstrated as a transcription activator of PU.1 in myeloid 
cell lines and in erythroleukimia (Hegde et al., 2009; Panopoulos et al., 2002). 
However, whether STAT3 is the upstream regulator of PU.1 in the 
proliferation and differentiation of neutrophils is unknown. Moreover, it is 
reported that STAT3 augments the transcriptional activity of C/EBPα by up-
regulating C/EBPα expression level upon G-CSF stimulation (Numata et al., 
2005), yet controversial, as another group stated that STAT3 did not change 
C/EBPα expression but instead influenced the duration of its occupancy on the 
promoter region of target genes in order to modulate the transcription of target 
genes (Zhang et al., 2010). Therefore, whether the repressive role of STAT3 in 
granulopoiesis is exerted through the classic myeloid lineage determinate 
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transcription factors or through other downstream targets requires further 
elucidation.  
      Last but not least, STAT3 has been suggested to be involved in epigenetic 
regulation of the genome by either direct targeting histone/DNA modifying 
enzymes or associating with the enzymes to alter epigenetic status, 
contributing to the reprogramming process during development, immunity and 
tumor transformation (Bagnyukova et al., 2008; Gong et al., 2007; Iliopoulos 
et al., 2009). Participation of STAT3 in the epigenetic regulatory machinery 
has been observed during the development of Th17 cells (Durant et al., 2010), 
implying a potential epigenetic regulatory role of STAT3 in hematopoiesis. 
The observation that the duration of C/EBPα occupancy on the c-myc 
promoter is altered in the absence of STAT3 (Nguyen-Jackson et al., 2010), 
strongly suggests STAT3-mediated epigenetic modification on the promoter as 
the regulatory mechanism. Hence, investigation on the STAT3-regulated 
epigenetic machinery which is either STAT3 downstream targets or co-
recruited to the STAT3 target genes is a new field to explore. 
 
1.4 Aim of Work 
STAT3 has been demonstrated to play a negative role in granulopoiesis in 
vivo, although little is known about the molecular mechanisms that regulate 
neutrophil proliferation and differentiation. 
      Tie2 expression can be detected as early as embryonic day 8.5 (Schnurch 
and Risau, 1993), and these early embryonic Tie2+ cells possesses the 
potential to give rise to both endothelial and hematopoeitic lineages (Lancrin 
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et al., 2009). Hence, the TIE2 gene promoter drives Cre expression leading to 
gene deletion in both bone marrow and endothelial cells. Although STAT3 has 
been indicated to be a negative regulator in granulopoiesis, whether it plays a 
part in early hematopoiesis was not assessed due to the limitation of LysM-Cre 
models. TIE2 promoter-driven Cre is able to drive the deletion of STAT3 in 
primitive hematopoietic stem cells, providing a good model to study the role 
of STAT3 in early hematopoiesis. In this study, the profiles of hematopoietic 
stem cells and various progenitor cells in STAT3-deficient bone marrow was 
inspected to reveal any possible roles of STAT3 in early hematopoiesis, 
especially in the regulation for lineage determination. 
      The major objective in this study is to investigate role of STAT3 in 
granulopoiesis and the pathogenesis of neutrophilia in the mice with targeted 
deletion of STAT3 in the bone marrow. The disrupted neutrophil homeostasis 
was suspected to be caused by intrinsic defects inherited in STAT3-deficient 
hematopoietic progenitor cells leading to over-activated granulopoiesis, thus 
underlying molecular mechanisms for the STAT3-regulated granulopoiesis 
was investigated. The expression levels of the classic myeloid driving factors 
in STAT3-deficient neutrophil granulocytes were examined. In addition, other 
factors that have been implicated in the regulation of myeloid proliferation and 
differentiation were also inspected to look for STAT3 downstream targets in 
the regulation of granulopoiesis. 
      Since STAT3 has been demonstrated as a player in the epigenetic 
regulation of a variety of biological processes, thus any possible role of 
STAT3 in epigenetic regulation of granulopoiesis is of great interest. Using 
conditional knockout mice model, the expression of a bundle of epigenetic 
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factors in STAT3-deficient granulocytes was determined to explore potential 














STAT3-CFF homozygous STAT3-deleted mice were generated by two step 
crossing of mice homozygous for a STAT3 allele with two loxP sites in 
introns 17 and 20 (STAT3-FF) with TIE2-Cre+ mice. Breeders of each 
genotype were transferred from Fu’s lab in US (Welte et al., 2003). The 
genotype of the offspring was determined by PCR with the following primers. 
I-17F (5'-ATTGGAACCTGGGACCAAGTGG-3') and E-17B (5'-
ACATGTACTTACAGGGTGTGTGC-3') yield a 490-bp product with the WT 
STAT3 allele and a 520-bp product with the F allele. CreF (5'-
CGATGCAACGAGTGATGAGG-3') and CreB (5'-
CGCATAACCAGTGAAACAGC-3') yield a 300-bp PCR product with the 
TIE2-CRE transgene. STAT3-CFF and sex-matched   littermate STAT3-FF 
(occasionally STAT3-F+ were used if littermate STAT3-FF was not available) 
were analyzed at 4-6 weeks of age if not specified otherwise. CD45.1 
congenic mice were kindly donated by Dr Daniel.G. Tenen (National 
University of Singapore). All mice were on C57BL/6 genetic background and 
housed in the specific-pathogen-free facility in National University of 
Singapore.  
 
2.2 Differentiation of Bone Marrow-Derived Macrophages (BMDM) 
L929-cell conditioned medium (LCMM) was prepared as previously described 
as a source of granulocyte/macrophage colony stimulating factor (Englen et al., 
1995). BM nucleated cells from STAT3-CFF and control STAT3-FF were 
suspended in RPMI1640 (Gibco, Invitrogen) supplemented with 10% FBS, 30% 
LCMM, 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine 
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(RPMI-LCMM), and seeded 10 ml in 10 cm tissue culture dish in a total 
number of 10 million per dish for STAT3-FF cells and 6 million per dish for 
STAT3-CFF cells as STAT3-CFF BMDM grew faster than the control. The 
cells were incubated at 37oC in a 5% CO2 atmosphere. Four days after seeding, 
an extra 10 ml of fresh complete RPMI-LCMM medium was added per dish 
and incubated for an additional 3 days. To obtain the BMDM, the supernatant 
was discarded and the attached cells were washed with sterile PBS, followed 
by RNA extraction, protein harvest or ChIP assays.  
 
2.3 Harvest of Bone Marrow, Peripheral White Blood Cells, and 
Splenocytes 
After the mouse was euthanized with CO2, femurs and tibias of both sides 
were dissected out from surrounding muscles and tendons and thrilled in cold 
PBS. In cell culture hood, both ends of the femur or tibia were cut off, and 
bone marrow (BM) was flushed using a 27 gauge needle connected to a 1 ml 
syringe in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Invitrogen) 
supplemented with 10% Fetal Bovine Serum (FBS) (Hyclone, Thermo 
Scientific) (complete DMEM) into a polystyrene tube through a cell-strainer 
cap (BD Falcon). The cells were pelleted down, suspended in 1 ml in red 
blood cells (RBC) lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM 
EDTA) and incubated for 10 min on ice. The osmotic pressure was restored by 
adding 5 ml or more DMEM complete medium.  
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      Mouse blood was withdrawn by cardiac puncture using a 18 gauge needle, 
followed by RBC lysis in 20X volume RBC lysis buffer. Peripheral white 
blood cells (WBCs) were obtained after RBC lysis and resuspended in PBS.  
      Spleen was meshed through 70 µm cell strainer (Fisher Scientific) 
followed by RBC lysis. The number of nucleated splenocytes was counted 
with CountessTM (Invitrogen). 
 
2.4 Blood Count Analysis 
After the mouse was euthanized with CO2, blood was sampled by cardiac 
puncture using a 18 gauge needle. The blood samples were kept in K2EDTA-
coated tubes (BD Microtainer) which contain anticoagulant K2EDTA to 
prevent clotting. 20 µl of blood was used for blood count analysis by 
HemavetTM 950 (Drew Scientific, USA). 
 
2.5 Bone Marrow Transplantation 
Congenic CD45.1 mice were subject to lethally irradiation (8.5 Gy) 1 day 
before BM transplantation. 1 million BM nucleated cells from STAT3-CFF 
and STAT3-FF control mice (CD45.2) in 200 µl serum-free α-MEM (Gibco, 
Invitrogen) medium were injected to each anesthetized CD45.1 recipient 
mouse retroobitally using a 30 gauge needle. The recipient mice were 





2.6 Fluorescence-Activated Cell Sorting (FACS) Analysis and Cell 
Sorting  
BM nucleated cells, peripheral WBCs and splenocytes in FACS staining 
buffer (PBS + 3% FBS) suspensions were treated with anti-CD16/32 (Fc-
receptor antibody to prevent nonspecific binding) (BD Pharmingen) and 
followed by staining with labeled antibodies as indicated for 15 min on ice. 
Anti-lineage-APC, anti-sca-1-PE-cy7, and anti-flt3-PE-TexasRed were 
purchased from BD pharmingen, the rest were from eBioscience including 
anti-ckit-APC-cy7, anti-CD34-FITC, anti-CD127-PE, anti-Gr-1-FITC, anti-
CD11b-PE, anti-CD45.1-PE, anti-CD45.2-APC. The cells were washed twice 
and resuspended in with FACS staining buffer. Analysis was performed on 
LSRII flow cytometer (BD Biosciences) and data was processed by FlowJo 
software (Tree star, USA). For cell sorting, cells were passed through 70 µm 
cell strainer to make single cell suspension before sending to sorting which 
was carried out by FACSAria (BD Bioscience) for HSPCs, and BM 
granulocytes were sorted by Sy3200 cell sorter (Sony Biotechonoly, USA). 
 
2.7 RNA Extraction and Real-Time PCR 
Total RNA was extracted from cells with RNeasy kit (Qiagen) according to 
the manufacturer’s instruction. Complementary DNA (cDNA) was 
synthesized with M-MLV reverse transcriptase (Promega) using oligo dT 
primers. Gene expressions were measured by 7300 real-time PCR system 
(Applied Biosystems) with SYBR qPCR kit (KAPA Biosystems). The 
sequences of PCR primers are listed in the table below. The information about 
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the primers for the screening of epigenetic factors are in the supplementary 
Table S1. 
Table 2.1 Real-Time PCR primers 























Forward GTT TAC CGA ATT GTC CCC GAG 















2.8 May-Grunwald-Giemsa and HE Staining 
105 sorted BM immature and mature granulocytes suspended in 200 ml PBS 
supplemented with 5% FBS were loaded in Shandon Cytofunnel (Thermo 
Scientific) and cytospinned onto glass slides with CytoSpin 4 cytocentrifuge 
(Thermo Scientific) at 800 rpm for 3 min. The cytospin specimen was fixed 
with methanol for 15 min, then stained in diluted May-Grunwald stain (Merck) 
(1 part diluted with 1 part buffer made from 111374 buffer tablets pH6.8 
(Merck)) for 6 min, followed by rinsing and staining with diluted Giemsa stain 
(Merck) (1 part diluted with 9 parts buffer made from 11374 buffer tablets 
pH6.8). The slides were rinsed off stains and air dried, and then subject to 
microscopic examination with Axioplan 2 imaging system (Zeiss). 
      For histological analysis of colon and liver, tissues were fixed in 4% 
paraformaldehyde in PBS, embedded in paraffin, sectioned, and stained with 
hematoxylin and eosin. 
 
2.9 Western Blot 
Isolated BM granulocytes or culture BMDM were lysed with cell lysis buffer 
(50 mM Tris-Cl, pH7.8, 150 mM NaCl, 1% v/v SDS, 1% v/v NP40 and Roche 
protease inhibitor tablet according to manufacturer’s guide). Lysates were 
boiled at 96oC for 5 min before resolved by 7.5% SDS-PAGE. The proteins 
were transferred from the gel to PVDF membrane at 400mA for 90 min in 
western transfer buffer (192 mM glycine, 25 mM Tris base, 20% v/v 
methanol). Membranes were blocked with 5% fat-free milk in PBS-T (PBS 
with 0.2% Tween 20) for 1 hour at room temperature, and incubated with 
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indicated primary antibody (1:1000 dilution in PBS-T + 1% milk) overnight at 
4oC and respective secondary antibody (1:5000 dilution in PBS-T + 1% milk) 
for 1 hour at room temperature to probe the protein of interest. Anti-IRF8, 
anti-Stat3, anti-Actin, anti-Tubulin, and anti-goat antibodies were purchased 
from Santa Cruz; anti-pStat3 was from Cell Signaling, anti-mouse and anti-
rabbit antibodies were from Invitrogen; anti-Sirt6 was purchased from Abcam. 
The membrane was incubated in ChemiLucentTM (Millipore) and exposed to 
the X-ray film which was developed by Konica SRX101A (Konica Minolta).  
 
2.10 UCSC Search 
UCSC custom tracks were constructed by the bioinformatic group from our 
lab based on the UCSC Genome Bioinformatics Site (www.genome.ucsc.edu). 
The UCSC custom track integrates published datasets on genome-wide 
STAT3 binding/occupancy profiling by high throughput chromatin 
immunoprecipitation and massive parallel sequencing (ChIP-Seq) in mouse 
embryonic stem cells and T lymphocytes, including GSE27708, GSE21669 
and GSE23681 (Durant et al., 2010; Ghoreschi et al., 2010; Ho et al., 2011). 
The enriched STAT3 binding was visualized as peaks along the chromosome, 
and the position of the binding site of interest was extracted from table 
browser in mm8 assembly version which was uplifted to current mm10 




2.11 Chromatin Immunoprecipitation (ChIP) 
ChIP assay was performed based on the standard protocol (Lee et al., 2006). 
On day 1, sorted BM immature granulocytes or cultured BMDM were 
crosslinked with formaldehyde solution to a final concentration of 1% for 10 
min at room temperature, and the reaction was stopped by adding glycine to a 
final concentration of 0.2M. The cells were pelleted down at 700g for 5 min at 
4oC and washed twice with PBS. The fixed cell pellet was store at -80oC. On 
day 2, the cell pellet was thawed on ice, followed by resuspension and 
incubation in cell lysis buffer 1 (50 mM HEPES-KOH, pH7.5, 140 mM NaCl, 
1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100, 1X protease 
inhibitor from Roche) at 4oC for 10 min on rocker. The cells were then 
pelleted at 10,000g for 5 min and resuspended in lysis buffer 2 (10 mM Tris-
HCl, pH8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1X protease 
inhibitor) briefly followed by pelleting. Lysate was resuspended in lysis buffer 
3 (10 mM Tris-HCl, pH8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% 
Na-Deoxycholate, 0.5% N-lauroylsarcosine, 1X protease inhibitor)  and 
sonicated for a total 5 min (10 sec on/50 sec off) with Vibra-CellTM VC 750 
(Sonics & Materials, US) at 20% power, generating fragments that were 
enriched in the length of 200-500 bp. While sonicating, the tube was immersed 
in ice-water bath to keep the sample chilled. After sonication, 1/10 volume of 
10% Triton X-100 was added to the lysate followed by centrifugation at 
20,000g for 10 min at 4oC to pellet debris. The cleared supernatant was left a 
small amount as input control, and the rest were divided into 2 parts which 
were incubated with agrose beads pre-coated with anti-Stat3 (c20, Santa Cruz) 
or rabbit IgG (Cell Signaling) for 2 hr at room temperature, followed by 
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washing with RIPA buffer (50 mM HEPES-KOH, pKa 7.55, 500 mM LiCl, 1 
mM EDTA, 1% NP-40, 0.7% Na-Deoxycholate) for 5 times. The bound 
material was eluted in elution buffer (50 mM Tris-HCl, pH8.0, 10 mM EDTA, 
1% SDS) at 65oC for 30 min with occasionally votaxing. The beads were 
pelleted down and the chromatin in the supernatant was reversed crosslink by 
incubating in 65oC oven overnight, together with the input control sample. On 
day 3, the DNA was extracted with phenol:chloroform:isoamyl alcohol 
(Sigma-Aldrich) following incubation with RNaseA (0.2 mg/ml final 
concentration) at 37oC for 2 hr and incubation with proteinase K (0.2 mg/ml 
final concentration) at 55oC for 2 hr. The DNA-containing aqueous layer was 
added in NaCl (200 mM final concentration) and glycogen (30 µg total) 
followed by incubation with 2X volume EtOH at -20oC for 30min, 
centrifugation at 20,000g for 5 min,  and washing with 80% EtOH. The final 
pelleted DNA was air dried and resuspended in 10 mM Tris-HCl, pH8.0. The 
immunoprecipitated DNA was analyzed by real-time PCR with primers 
specific to the promoter site of IRF8 and SIRT6: IRF8-Forward (5’-
GGAGTAAAGAGAGAAAAGGACTCCA-3’) and IRF8-Reverse (5’-
GGTCGCGCGAGCTAATTGA-3’); SIRT6-Forward (5’-
CACCCTCAGGCACGTATCTA-3’) and SIRT6-Reverse (5’-
GCTGCATAATTCACCGACAT-3’). 
 
2.12 Luciferase assay 
The promoter region of IRF8 gene was clone from mouse genome using 
P_IRF8_Forward (5’ - ATCGGCTAGCTCTCCAAACCTGAACGAC - 3’) 
and P_IRF8_Reverse (5’ - AGCCTCGAGCGCCTGCTTTTATAGATGG - 
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3’). The cloned promoter fragment was digested with NheI and XhoI, and then 
ligated into NheI and XhoI double-digested firefly luciferase reporter gene 
construct (pGL4) (Promega). The putative Stat3 binding site on IRF8 
promoter was mutated by amplifying the IRF8-promoter-containing pGL4 
construct with point mutation primer set, P_IRF8_mut_Forward (5’ - 
GGGACGTGCAAAAGTGATGGATCGGAAAGAGAGCGCTTC - 3’) and 
P_IRF8_mut_Reverse (5’ - GAAGCGCTCTCTTTCCGATCCATCACTTTT 
GCACGTCCC - 3’).  
      NIH3T3 cells were culture with DMEM supplemented with 10% FBS and 
antibiotics (penicillin and streptomycin) and seeded in 12-well plates 1 day 
prior to transfection. pGL4 vector containing IRF8 promoter or IRF8 promoter 
mutant was cotransfected with Renilla luciferase construct (Promega) which 
was used as an internal control for transfection efficiency. For each well, 0.4 
µg of IRF8 promoter- or IRF8 promoter mutant- driven firefly luciferase 
construct with 0.04 µg of Renilla construct was diluted in 50 µl of OPTI-
MEM® (Gibco, Invitrogen), followed by mixing with a second portion of 50 
µl OPTI-MEM® containing 1 µl Lipofectamine 2000TM transfection agent 
(Invitrogen). The mixture was incubated at room temperature for 20 minutes 
to allow the formation of DNA-liposome complex. The cells were pre-
incubated with 500 µl antibiotic-free DMEM for 2 hr prior to transfection, and 
the 100 µl transfection mixture was added into the medium for an incubation 
of 6 hr at 37oC. Subsequently, the transfection mixture was removed and the 
cells were grown in DMEM growth medium for 24 hr, followed by starvation 
in reduced serum medium (DMEM + 0.5% FBS) for another 16 hr. After 
starvation, cells were treated with 50 ng/ml IL-6 in reduced serum medium or 
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untreated for 6 hr. Cells were then washed with PBS,  lysed with 100 µl 
passive lysis buffer (Promega) and subject to one freeze-thaw cycle at -80oC. 
50 µl of cell lysate supernatant was used for analysis by a dual luciferase 
reporter assay (Promega) according to manufacturer’s instructions. The 
luciferase activity was expressed as the fold of the readings firefly in relative 
to the readings of renilla. Each transfection and luciferase assay was repeated 
three times before drawing any conclusions.  
 
2.13 Statistics 
Statistical significance was determined by one-tail, paired Student’s T test. 
The p value < 0.05 was considered significant. Unless otherwise specified, 












3.1 BM-Targeted Deletion of STAT3 leads to Altered Blood Counts and 
Neutrophilia 
Transgenic mouse strain with tissue specific disruption of STAT3 in the bone 
marrow (BM) cells was previously generated in Fu’s lab (Welte et al., 2003). 
In this strain, exons 18-20 of both STAT3 alleles are flanked by loxP 
sequences (STAT3-FF). Removal of exons 18-20, which encode the SH2 
domain for the recruitment of Stat3 to the receptor and subsequent activation, 
is expected to eliminate the function of Stat3 proteins. To achieve tissue 
specific deletion of STAT3, TIE2 gene promoter/enhancer cassette was 
designed to drive Cre expression in BM cells. The conditional STAT3 
knockout mice with TIE2-CRE, STAT3-FF, are designated as ‘STAT3-CFF’. 
Since the conditional knockout mice developed syndromes of neutrophilia and 
died within 4-6 weeks after birth, the frail STAT3-CFF mice could only be 
obtained by crossing of TIE2-CRE, STAT3-F+ (male) with STAT3-FF 
(female) (Figure 3.1b). The yield of STAT3-CFF in offspring was slightly 
below Mendelian ratio, but the STAT3-CFF mice appeared generally normal 
at birth, indicating the absence of severe defects during embryonic 
development. However, STAT3-CFF mice became obviously smaller than 
their siblings from 3 weeks of age onwards (Figure 3.1a). Moreover, the 
spleen of STAT3-CFF mouse was significantly enlarged, with higher weights 
compared with its littermate control (Figure 3.1c). Histological analysis 
showed mucosal erosion and transmural inflammation in the colon of STAT3-




         
 
                         
 







         








Figure 3.1 Characterization of the phenotypes of mice with targeted disruption 
of STAT3 in the bone marrow (STAT3-CFF). (a) STAT3-CFF mouse was 
generally smaller in size. (b) STAT3-CFF mouse was genotyped as Cre+, and floxed 
SH2 domain on both alleles. (c) The spleen of a 5-week-old STAT3-CFF mouse was 
significantly enlarged (6-week-old), and the weights of STAT3-CFF mice were 
generally higher than the littermate control mice. *p<0.05. (d) Histological analysis 
on the colon of STAT3-CFF showed mucosal erosion (arrow 1) and transmural 





      Our lab has previously reported the neutrophilic phenotype of STAT3 BM 
conditional knockout mice when they were firstly generated (Welte et al., 
2003), with detailed pathology yet to be resolved. In order to study the 
pathology of neutrophilia more closely, we examined the total blood cell 
constitutions in the peripheral blood of STAT3-CFF mice. Peripheral blood of 
5- to 6-week-old STAT3-CFF and littermate STAT3-FF control mice was 
sampled by cardiac puncture upon euthanization, and analysed by HemavetTM 
950 blood counter (Table 3.1). Under normal physiological circumstances, 
lymphocytes were the most abundent type of white blood cells (WBCs) in the 
blood of healthy control mice. On the contrary, a prominent expansion of 
neutrophils was observed in the peripheral blood of STAT3-CFF mice.  
Although the neutrophils were increased by 5 folds, the counts of lymphocytes 
did not alter much in STAT3-CFF mice. Hence, the significant change in the 
constitutions of blood WBCs, with an drastically increased percentage of 
neutrophils and a decreased percentage of lymphocytes, was mainly attributed 
to the expansion of peripheral neutrophils. The counts of other types of 
myeloid cells such as monocytes, eosinophils and basophils also increased in 
STAT3-CFF mice, but to a less extent compared with neutrophils, and they 
did not alter the constitutions of peripheral WBCs as significant as neutrophils 
did. Moreover, there was a remarkable reduction in RBC counts in STAT3-
CFF mice indicating they were suffering anemia, whereas the platelet counts 
were not severely affected. Overall, the enormous expansion of neutrophils in 
the peripheral blood, which is characterized as neutrophilia, was one the most 
prominent phenotypes of the mice with BM-specific deletion of STAT3. 
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Table 3.1 Differential blood counts of STAT3-CFF mice and STAT3-FF 
controls 
  STAT3-FF STAT3-CFF 
WBCs count (K/µl) % count (K/µl) % 
Neutrophils 1.554 ± 0.792  23.60 ± 3.42 7.984 ± 4.231 *** 55.08 ± 13.83 *** 
Lymphocytes 4.445 ± 2.213 67.21 ± 4.86 4.404 ± 1.137 33.97 ± 11.35 *** 
Monocytes 0.332 ± 0.208 5.48 ± 2.41 0.848 ± 0.414 *** 6.719 ± 3.59 
Eosinophils 0.172 ± 0.145 2.87 ± 2.09 0.383 ± 0.255 * 2.97 ± 2.15 
Basophils 0.056 ± 0.060 0.85 ± 0.85 0.132 ± 0.104 * 1.01 ± 0.84 
RBC 8276 ± 1752   4914 ± 1818 ***   
Platelets 1150 ± 704   1052 ± 294   
Peripheral blood samples from STAT3-FF control and STAT3-CFF mice were 
analyzed by HemavetTM 950 hematology system. Means ± SEM were obtained from 
10 pairs of mice aged from 4 weeks to 6 weeks old. *p<0.05; ***P<0.005. 
 
      To further characterize the neutrophilic phenotype, a time-course 
examination of peripheral neutrophil counts was performed. The frequency of 
neutrophils in blood WBCs at early and late stage of neutrophilia pathogenesis 
was analyzed by FACS analysis (Figure 3.2a) Blood was collected by cardiac 
puncture and RBCs were removed by RBC lysis buffer. WBCs were stained 
for the neutrophil marker, Gr-1 (Granulocyte differentiation antigen 1). There 
are normally two peaks of Gr-1-positive population in periphral WBCs and 
BM, designated here as Gr-1lo and Gr-1hi, representing immature and mature 
neutrophil granulocytes respectively (Hestdal et al., 1991). STAT3-CFF mice 
of 4 weeks of age exhibited higher levels of neutrophils in peripheral WBCs 
than the littermate control. The phenotype of neutrophilia exaggerated as the 
mouse growing up and the neutrophils invaded the the whole blood by week 6 
when the mouse was dying. Noticeably, the neutrophil counts in 6-week-old 
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STAT3-FF control exceeded the normal range, and it might be resulted from 
environment-induced inflammation which will be further discussed in the next 
chapter. Although the neutrophils expanded in 6-week-old control mice, two 
distinct populations of immature (Gr-1lo) and mature (Gr-1hi) neutrophil 
granulocytes was still maintained. STAT3-/- neutrophils, on the contrary, were 
mostly driven to the mature state at week 6.  
      It is known that spleen is one of the major sites where senescent 
neutrophils are cleared from the blood (Lovas et al., 1996), thus the frequency 
of neutrophils in the spleen was also examined. In healthy controls, neutrophil 
counts in the spleen were maintained at a very low level, whereas a 
remarkable expansion of neutrophils was observed in the spleen of STAT3-
CFF mice (Figure 3.2 b, c). The expansion of neutrophils in the spleen of 
STAT3-CFF was a cumulative event with age (Figure 3.2c), corresponding to 
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3.2 STAT3-/- HSCs Recapitulates Neutrophilia in Wild-Type Mice 
BM-targeted deletion of STAT3 in our transgenic mice is achieved by tissue-
specific expression of Cre driven by TIE2 gene promoter/enhancer cassette. It 
is known that Tie2 is expressed in both BM and endothelial cells (Schnurch 
and Risau, 1993). Thus, possible leaking expression of Cre in endothelial cells 
leading to STAT3 deletion in endothelium is a confounding factor in 
analyzing the transgenic mice.  In order to ensure the neutrophilic phenotype 
observed was mainly attributed to the deficiency of STAT3 in BM, BM 
mononucleocytes from STAT3-CFF mice (CD45.2) was transplanted into 
wild-type (WT) congenic variant recipient mice (CD45.1) for the function 
assessment.  
     BM mononucleocytes from either STAT3-CFF or control STAT3-FF mice 
were transplanted into the lethally irradiated WT congenic variant CD45.1 
mice. The reconstitution of peripheral blood was examined three months post 
BM transplantation when all the differentiated blood cells in the host at the 
time of transplantation had been turned over (Figure 3.3a). The peripheral 
blood cells at the time of examination were derived from transplanted STAT3-
/-
 HSCs, with a small fraction from the residual HSCs of the recipients. The 
origins of the differentiated blood cells were distinguished by the different 
isoforms of surface antigen CD45, i.e., CD45.2 for donor-origin cells and 
CD45.1 for recipient-origin cells. Three months after BM transplantation, in 
the recipients of STAT3-FF BM, over 70% of peripheral WBCs were derived 
from engrafted donor cells. While in mice receiving STAT3-/- BM cells, 
around 75% of the recipient’s peripheral WBCs were derived from the donor 
(Figure 3.3b), which was comparable to the control. These results indicate that 
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STAT3-/- HSCs had the potential of homing, and differentiation, and they 
could reconstitute peripheral blood with similar efficiency as control HSCs. 
      Furthermore, the amount of neutrophils in the recipient mice was 
determined. Mice receiving STAT3-/- BM exhibited tremendous expansion of 
neutrophils in peripheral blood as well as in BM by three months post-
transplantation, recapitulating the neutrophilic phenotype of STAT3-CFF 
(Figure 3.3c). In the mice implanted with STAT3-/- BM, most of the peripheral 
WBCs and BM cells were found to be neutrophils, although about 20% of 
peripheral WBCs were derived from host’s residue HSCs. The hematopoiesis 
of recipient’s residual HSCs was skewed towards granulopoiesis in the 
presence of STAT3-/- blood cells, suggesting the involvement of external 
triggers in the pathology of neutrophilia, possibly the cytokines produced in 
the context of chronic inflammation. The data from BM transplantation 
experiment confirms that the neutrophilic phenotype was caused majorly by 
the intrinsic defects in STAT3-deficient BM. Therefore, further investigations 
was carried out using STAT3-CFF as the model to study the endogenous role 
of STAT3 in granulopoiesis as well as its role in the pathology of neutrophilia. 
  
             












Figure 3.3 STAT3-/- BM was able to recapitulate neutrophilia in WT mice. The 
work flow diagram for bone marrow transplantation is presented in (a). CD45.1 
congenic mice were irradiated at 8.5 Gy, and each was transplanted with 1 million of 
STAT3-CFF or STAT3-FF BM mononucleocytes (CD45.2). (b) Three months later, 
the peripheral blood of the recipients was sampled and stained with anti-CD45.1 and 
anti-CD45.2 antibodies conjugated with PE and APC respectively. The samples were 
analyzed by FACS and the percentage of donor- or recipient- derived cells is 
indicated accordingly. (c) Meanwhile, blood WBCs and BM mononucleocytes of the 
recipient mice were stained for Gr-1, followed by FACS analysis. The figures present 




3.3 STAT3 Regulates Lineage Specification in Early Hematopoiesis 
3.3.1 STAT3 Deficiency Leads to Expansion of Myeloid Progenitors 
To study the role of STAT3 in granulopoiesis, development of granulocyte 
progenitors from hematopoietic stem cells (HSCs) in early hematopoietic 
process was investigated. First, we examined the profile of hematopoietic stem 
and progenitor (HSPC) subpopulations in mouse BM. BM nucleated cells 
from 6-week-old STAT3-CFF and littermate controls were stained with 
various HSPC surface markers and subject to FACS analysis. Assorted lineage 
markers including CD3e, B220, CD11b, Gr-1 and TER-119 was employed to 
exclude differentiated T- and B-lymphocytes, granulocytes, monocytes/ 
macrophages and erythrocytes. The frequency of lineage negative (Lin-) cells 
seemed comparable in STAT3-deficient BM and its littermate STAT3-FF 
controls (~5%) (data not shown), but the profile of subpopulations of HSPC in 
BM lin- cells was altered remarkably in the absence of STAT3.  
      Compared with STAT3-FF controls, BM of STAT3-CFF mice displayed a 
significantly higher percentage of multiple progenitor (MP) population, 
determined by lin-sca-1-ckit+ (Figure 3.4a). The MP population mainly 
consists of CMP (CD34+CD16/32int), GMP (CD34+CD16/32hi), and MEP 
(CD34-CD16/32lo), the progenitors for common myeloid, granulocyte/ 
macrophage and megakaryocyte/erythrocyte lineages respectively. The 
percentage of CMP was slightly decreased in the MP population in STAT3-
CFF compared with the control, but the absolute frequency of CMP in the BM 
Lin- cells was actually increased as the MP population expanded extensively 
(Figure 3.4a, b). Although CMP is the common progenitor for GMP and MEP, 
it preferentially differentiated into GMP in STAT3-/- BM as GMP expanded 
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significantly (P<0.01) at the expense of MEP (P<0.05). These observations 
indicate that hematopoiesis towards granulocyte/macrophage lineage was 
uplifted in STAT3-/- BM HSPCs. 
In addition to the development of myeloid progenitors, other types of HSPCs 
were also investigated for a comprehensive understanding of the role(s) of 
STAT3 in early hematopoiesis (Figure 3.4c). The frequency of long-term 
repopulating HSCs (LT-HSC) and short-term HSCs (ST-HSC) seemed slightly 
reduced in LSK (Lin-Sca-1+cKit+) fraction. Considering the increased 
percentage of LSK fraction in the BM, the absolute frequency of LT-HSC was 
unchanged in STAT3-CFF BM compared with control BM, whereas the 
frequency of ST-HSC was marginally increased. The STAT3-deficient 
multipotent progenitor (MPP) fraction was raised both proportionately and in 
absolute number, indicating that the STAT3-deficient ST-HSCs were active in 
proliferation and differentiation. Expanding STAT3-/- MPPs further 
differentiated and committed to lineage-restricted progenitors such as CMP 
and GMP. In contrast to the myeloid progenitors, the development of 
lymphoid lineage was found impaired in the absence of STAT3 (Figure 3.4c), 
as the common lymphoid progenitor CLP, which was gated as Lin−cKitlowSca-
1lowCD127+, was mostly diminished in STAT3-/- BM.  
      All together, the data demonstrated a skewed differentiation of STAT3-/- 
HSCs towards myeloid lineage, especially the granulocyte/macrophage 
lineage at the expense of lymphoid and megakaryocyte/erythrocyte lineages in 
the BM. 
 








                  
              





Figure 3.4 STAT3 deficiency led to expansion of myeloid progenitors. (a) Profiles 
of bone marrow (BM) hematopoietic stem and progenitor (HSPC) subpopulations in 
BM lineage negative cells from STAT3-CFF and control STAT3-FF. Multiple 
progenitor (MP) population was determined as lin-Sca-1-cKit+, and sub-classified into 
common myeloid progenitor (CMP), granulocyte/macrophage progenitor (GMP) and 
megakaryocyte/erythrocyte progenitor (MEP) based on the expression level of 
CD16/32 and CD34. Numbers indicate the percentage of gated cells in the parental 
gating. (b) Percentage of CMP, GMP, and MEP in BM lineage negative population 
was determined by FACS. Short bars indicate the means from 6 pairs of STAT3-CFF 
and STAT3-FF mice. *p<0.05; **p<0.01; ***P<0.005. (c) Profiles of hematopoietic 
stem cell (HSC) and common lymphoid progenitor (CLP) subpopulations in BM 
lineage negative cells from STAT3-CFF and STAT3-FF control. Lin-Sca-1+cKit+ 
(LSK) fraction was subclassified to long-term HSC (LT), short-term HSC (ST) and 
multipotent progenitor (MPP) based on the expression of CD34 and Flt3. CLP was 
defined as Lin-Sca-1lowcKitlowCD127+ cells. Numbers indicate the percentage of gated 




      In addition to BM hematopoiesis, extramedullary hematopoiesis (EH) was 
examined in the spleen and liver of STAT3-CFF mice. The nucleated 
splenocytes were stained for myeloid progenitor markers for the determination 
of myeloid specification in EH. In healthy control mice, there were very few 
Lin- cells (0.4%), and hardly any progenitors in the spleen (Figure 3.4d). In 
STAT3-CFF spleen, on the contrary, a huge expansion of Lin- cells (3.9%) 
was observed. Moreover, all types of the myeloid progenitors expanded 
extensively, indicating an active process of EH in the spleen. Surprisingly, 
MEP expansion was prominent in STAT3-CFF spleen, while CMP and GMP 
expended to a much less extent, displaying a very different hematopoietic 
profile from BM hematopoiesis in STAT3-CFF mice. The formation of MEP 
during EH was preferred in STAT3-CFF mice, presumably serving as a 
compensation mechanism for the sustained anemia in STAT3-CFF. In addition, 
small aggregates of cells with intensely basophilic nuclei (erythroid) 
accompanying with small fractions of immature and mature myeloid cells 
were observed in the liver of STAT3-CFF (Figure 3.4e). The typical 
morphological features of liver EH suggest an active hematopoietic event in 





                               
 
Figure 3.4 (d) Profiles of HSPC subpopulations in the spleen of STAT3-CFF and 
STAT3-FF control mice by FACS analysis. (e) Histological examination of 
extramedullary hematopoiesis in the liver which was characterized by small 





3.3.2 Altered Expression Profile of Lineage Determinate Genes in STAT3-
deficient HSPCs 
To further investigate the changes in the early hematopoiesis in STAT3-/- BM 
at the molecular level, HPSCs were isolated by flow cytometry based on the 
expression of Lin-cKit+, which included HSCs, MPPs and various lineage-
restricted progenitors. The mRNA expression levels of a number of key 
lineage determinate genes in the HSPC population were determined by real-
time PCR. 
      As shown in the last panel of Figure 3.5a, TIE2-promoter driven Cre 
achieved complete deletion of STAT3 in early HSPCs. Unexpectedly, most 
important myeloid determinate genes were not changed as significantly as the 
expansion of STAT3-/- myeloid progenitors. The expression of key myeloid 
determinate genes such as CEBPa and SPI1, which encodes for PU.1, was 
marginally upregulated in STAT3-/- HSPCs, whereas the expression level of 
CEBPb was not changed as it may act at a later stage of myeloid 
differentiation (Figure 3.5a). Noticeably, the expression of the key driving 
factors for B-lymphoid lineage such as EBF and PAX5 were significantly 
impaired in the absence of STAT3, while the level of E2A was also 
moderately reduced. The compromised expression of lymphoid lineage 
driving factors in STAT3-/- HSPCs was associated with the impaired 
development of lymphoid progenitors (Figure 3.4c). In addition, the 
expression level of GATA1, a major determinant for megakaryocyte/ 
erythrocyte lineage, was significantly decreased in STAT3-/- HPSCs, implying 
a reduced potential for megakaryocyte/erythrocyte differentiation and 




Figure 3.5 Expression profile of lineage determinate genes in 
HPSCs were isolated from 
mice by flow cytometry based on the expression of l
from isolated HPSCs and expression levels of indicated genes were determined by 
real-time PCR. The values of expression level of each gene are relative folds to the 
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      Disruption of STAT3 in HSPCs altered the expression profile of key 
lineage determinate genes, suggesting a potential role of STAT3 in regulating 
lineage specification. It is known that the functional significance of 
transcription factors is often associated with the expression level at the critical 
time window. Hence, the expression of STAT3 at mRNA level was further 
analyzed in fractions of HSCs and various progenitors that were sorted by the 
combination of surface markers described earlier (Figure 3.5b). STAT3 was 
highly expressed in HSCs and MPPs, suggesting a potentially important role 
in the early phase of hematopoiesis, probably by regulating HSC 
differentiation and lineage specification (Figure 3.4c). Once the cells were 
committed to assorted lineage-restricted progenitors and beyond, which is 
identified as MP and intermediate progenitor (IP), the expression of STAT3 
seemed downregulated. These observations imply that the function of STAT3 
during hematopoiesis could occur at the very initial stage, as early as HSC and 
MPP. 
      To further verify the role of STAT3 at early stage of hematopoiesis, a class 
of transcription factors and epigenetic factors were screened in STAT3-/- HSCs 
and MPPs. We identified a couple of interesting genes that might be STAT3 
downstream targets and may play important roles for the regulation of HSC 
self-renewal and lineage specification. This part is currently under 
investigation by other lab members, and will not be discussed in the thesis. 
Here EBF was shown as an example to demonstrate the potential role of 
STAT3 in regulating very early hematopoietic progenitors. HSC fraction and 
MPP fraction were sorted based on the expression of lin-sca-1+ckit+Flt3- and 
lin-sca-1+ckit+Flt3+ respectively. Expression of EBF was diminished in 
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STAT3-/- HSC and MPP cells (Figure 3.5d), suggesting that STAT3 may 
regulate the transcription of EBF in early hematopoiesis for the specification 
of B-lymphoid lineage. 
      Overall, these findings suggest that STAT3 may play important and 
diverse roles for lineage determination in HPSCs. STAT3 might promote the 
expression of lineage determinate genes for lymphoid and megakaryocyte/ 
erythrocyte specification, while suppress the myeloid genes to a less extent. 
The expansion of CMP and GMP in HPSCs might be, at least partially 
attributed to the compromised potential for lymphoid and megakaryocyte/ 
erythrocyte development, streaming the hematopoietic differentiation into 
myeloid lineage. 
  










Figure 3.5 (b) Hematopoietic stem cell (HSC), multipotent progenitor (MPP), 
multiple progenitor (MP) and intermediate progenitor (IP) were sorted from WT mice 
according to the combinatorial surface markers. (c) mRNA expression level of 
STAT3 in these sorted factions of HSPCs was determined by real-time PCR, and 
expressed in relative fold to GAPDH. (d) HSC and MPP fraction were isolated from 
BM of STAT3-CFF and STAT3-FF control mice. mRNA expression level of EBF in 






3.4 STAT3 Suppresses Granulocyte Expansion during Terminal 
Granulopoiesis 
3.4.1 Progressive Expansion of Granulocytes in STAT3-/- BM 
As expansion of myeloid progenitors was observed in STAT3-/- BM, we 
further investigated the role of STAT3 in terminal granulopoiesis in order to 
find out its possible role in the contribution to the neutrophilic phenotype in 
STAT3-CFF mouse.  
      BM mononucleocytes were harvested at different time-points and stained 
for Gr-1, the major granulocyte marker,  as well as CD11b which is expressed 
on monocytes, macrophages and granulocytes, followed by FACS analysis.  
There were Gr-1lo and Gr-1hi populations in the BM, representing immature 
and mature granulocytes, which was similar as in the periphery. When the 
control mice went through adolescence from postnatal week 4 to week 6, their 
innate immunity seemed to experience major changes in the composition of 
leukocytes with a significant rise in the granulocyte compartment (Figure 3.6a, 
upper panel), which was resulted from the development and maturation of self 
immune system since immunity from mother’s milk discontinued (Pinheiro et 
al., 2011). The abundancy of granulocytes in BM was well maintained in the 
healthy control mice since week 6 and throughout the adulthood (data not 
shown).  
      In the absence of STAT3, the development and maturaton of granulocyte 
compartment seemed faster as the 4-week-old STAT3-CFF mice showed 
higher levels of immature and mature granulocytes in the BM than their 
littermate controls. The abundancy of BM immature and mature granulocytes 
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in STAT-CFF mice was at a similar level as that in healthy adults (Figure 3.6a, 
b). STAT3-/- granulocytes continued expanding with time, but the 1:2 ratio of 
immature to mature granulocytes was maintained until week 5. However, by 
week 6, a massive production of immature granulocytes interupted the proper 
scheme of granulocyte maturation with a large quantity of granulocytes 
expressing intermediate levels of Gr-1 and the clear distinction between 
immature and mature granulocytes was lost. Nevertheless, although expanding 
dramatically, STAT3-/- immature and mature granulocytes maintained their 
morphology fairly well (Figure 3.6c). The immature granulocytes held an 
intact spherical nucleus with minimal cytoplasmic compartment, whereas the 
mature granulocytes possessed segmented or banded nucleus. These 
observations suggest that STAT3 might control the granulocytes homeostasis 









 Figure 3.6 Progressive expansion of granulocytes in STAT3
frequency of BM granulocytes was examined for STAT3
FF mice at 4-, 5-, 6-weeks of age. BM mononucleocytes were stained for CD11b and 
Gr-1, followed by FACS analysis. BM
identified as CD11b+Gr
percentage of the gated population in the whole BM nucleated cells
presentation of the average frequency of immature and mature granulocytes. Values 
were means of 5 independent pairs at each time point. *p<0.05; **p<0.01; 
***p<0.005. (c) Morphology of BM Immature and mature granulocytes (Gr) from a 
pair of 6-week old STAT3
granulocytes were sorted by flow cytometry based on the surface markers indicated in 
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3.4.2 STAT3 Regulates IRF8 Expression in BM Immature Granulocytes 
We have observed an abnormal expansion of STAT3-/- BM immature 
granulocytes. To further study the underlying molecular mechanism for the 
negative regulatory role of STAT3 in BM terminal granulopoiesis, a group of 
myeloid determinate genes were examined in isolated BM immature 
granulocytes. Unexpectedly, the expression levels of the key players in 
terminal granulopoiesis such as SPI1, C/EBPa/b/e and GFI1 were not altered 
in STAT3-/- BM immature granulocytes which expanded massively though 
(Figure 3.7a). These findings suggest the regulatory role of STAT3 in 
granulocyte expansion may not exert through the classic pathways in 
granulocyte development.  
       It was reported that mice with a null mutation of IRF8 exhibited a 
prominent myeloproliferative disorder characterized by a clonal expansion of 
undifferentiated myeloid cells (Holtschke et al., 1996), suggesting IRF8 is an 
important player in regulating the proliferation of immature myeloid cells. 
Thus, the expression level of IRF8 in the STAT3-/- immature granulocytes was 
tested. We observed a significant reduction in IRF8 mRNA level in STAT3-/- 
immature granulocytes (Figure 3.7b). Consistently, the level of Irf8 protein 
was reduced in STAT3-/- immature granulocyte (Figure 3.7c). Interestingly, 
the expression of IRF8 dropped as the control BM immature granulocytes 
went through maturation, and the level was very low in mature granulocytes, 
suggesting that IRF8 may play a critical role specifically in the immature stage. 
The expression of IRF8 in mature granulocytes was independent of STAT3, 
although activated form of Stat3 proteins were detected in the mature 
granulocytes. Moreover, we found the absence of STAT3 did not affect the 
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expression of IRF8 in HSPCs (Figure 3.7d). The effect of STAT3 on IRF8 
expression occurred neither at the early stage of hematopoiesis, nor in the 
terminally differentiated mature granulocytes, but only in a short time window 
during granulopoiesis, that is in the immature granulocytes. These data imply 
that IRF8 might be a player in STAT3-regulated granulopoiesis mainly at the 
immature stage.  
  
  
Figure 3.7 Expression of IRF8 was impaired in STAT3
granulocytes. BM immature granulocytes from STAT3
FF control mice were 
CD11b+Gr-1lo. (a) The expression level of a number of classic myeloid determinate 
genes was determined in STAT3
values of expression level of each gene 
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Figure 3.7 (b-d) CD11b
mature granulocytes were sorted from BM of STAT3
mice by flow cytometry
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3.4.3 Stat3 Directly Binds to the Promoter Site of IRF8 and Induces Gene 
Transactivation 
We observed a remarkable reduction in the expression of IRF8 in STAT3-/- 
immature granulocytes. Then we asked whether IRF8 transcription was 
directly regulated by Stat3. 
      The bioinformatic group from our lab has established a customized UCSC 
platform, which integrated the published ChIP-Seq datasets of genome-wide 
STAT3 binding, for an easy access and visualization of Stat3 binding sites on 
the genes of interest. From a T cell-based STAT3 ChIP-Seq data set published 
recently, an enriched Stat3 binding was detected on the promoter region of 
IRF8, around 80~470 bp upstream of the transcription start site (Figure 3.8a) 
(Durant et al., 2010). The data suggest IRF8 might be a downstream target of 
STAT3. Hence, the binding of Stat3 on this putative site of IRF8 promoter 
region was examined in BM immature granulocytes by chromatin 
immunoprecipitation (ChIP) assay. Wild-type BM immature granulocytes 
were purified by flow cytometry based on the expression of CD11b+Gr-1lo. 
After cell sorting, Stat3 binding was reinforced by treating the cells with 50 
ng/ml IL-6, the classic Stat3 activator, for 1 hour, followed by ChIP analysis. 
Enrichment of Stat3 binding on the promoter region of IRF8 was observed in 
BM immature granulocytes upon IL-6 stimulation (Figure 3.8b). The weak 
binding in the untreated control cells was most likely due to the starvation 
during the processing and sorting period. Nevertheless, with stimulation, Stat3 
diaplayed a strong capability to bind on IRF8 promoter, suggesting its 
potential direct regulatory role in IRF8 transcription.   
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      In order to confirm that Stat3 transcriptionally activates the expression of 
IRF8, luciferase reporter assay was performed. A fragment of IRF8 promoter 
region, which is about 350 bp upstream of transcription start site and contains 
Stat3 binding consensus sequence “TTCXXXGGA”, was cloned into firefly 
luciferase reporter construct. A IRF8 promoter mutant was also generated by 
mutating three neuclotides in Stat3 binding consensus sequence TTC to GGA. 
NIH3T3 cells were cotransfected with IRF8 promoter- or IRF8 promoter 
mutant- driven firefly luciferase reporter construct togeter with renilla 
luciferase reporter construct which served as an internal control for 
transfection efficiency. The transfected cells were starved in reduced serum 
medium overnight, followed by 6hr treatment of 50 ng/ml IL-6. IRF8 
promoter activity was significantly upregulated upon IL-6 stimulation, 
resulting in increased expression of luciferase and ultimately increased 
luciferase activity assessed by dual luciferase reporter assay. Moreover, the 
IL-6-induced promoter activity was abolished when Stat3 binding consensus 
sequence in the promoter was mutated (Figure 3.8c). These results suggest that 
Stat3 could regualte IRF8 promoter activity and induce IRF8 transcription in 
response to IL-6 stimulation. 
  
                
 
Figure 3.8 Binding of STAT3
on the promoter site of IRF8 from 
(Durant et al., 2010) 
domenstration of searching for potential STAT3 targeted genes. 
the putative site in IRF8 promoter region was examined by ChIP assay in purified 
(c) 
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BM CD11b+Gr-1lo immature granulocytes with and without IL-6 (50 ng/ml) 
stimulation, indicated by IL-6 and control respectively. IgG served as a negative 
control for non-specific binding. (c) NIH3T3 cells were transfected with IRF8 
promoter- or IRF8 promoter mutant (mut)- driven firefly luciferase reporter construct 
togeter with renilla luciferase reporter construct which served as an internal control 
for normalization. The transfected cells were starved in reduced serum medium 
overnight, followed by treatment of 50 ng/ml IL-6 for 6 hr. Cell lysates were subject 
to a dual luciferase reporter assay, and relative luciferase values are indicated, which 





3.5 Epigenetic Regulation of STAT3 in Myeloid Cells 
STAT3 has been implicated to play critical roles in the epigenetic 
reprogramming during various biological processes (Bagnyukova et al., 2008; 
Gong et al., 2007; Iliopoulos et al., 2009). These observations led us to 
speculate possible regulatory mechanism of STAT3-regulated epigenetic 
reprogramming during terminal granulopoiesis. Recently, STAT3 has been 
proposed to regulate epigenetic reprogramming by modulating the expression 
of certain epigenetic factors (Guo et al., 2012). Hence, the expression levels of 
a group of epigenetic factors from different families were tested in STAT3-/- 
BM immature granulocytes.  
      A PCR primer library for a class of epigenetic factors was constructed in 
Fu’s lab, including families of DNA methyltransferases/demethylases, histone 
methyltransferases/demethylases, histone acetyltransferases/deacetylases and 
some other post-translational modifying enzymes. Part of the PCR primer 
library was used to screen the expression profile of about fifty epigenetic 
factors in STAT3-/- BM immature granulocytes to search for potential STAT3 
targets. The expression levels of the epigenetic factors in isolated STAT3-/- 
immature granulocytes were determined by real-time PCR. The levels were 
standardized to GAPDH, and then normalized to that of control STAT3-FF 
immature granulocytes, thus the values greater than 1 represents upregulation 
in STAT3-deficient cells, and vice versa. The expression levels of many 
selected epigenetic factors changed marginally in the absence of STAT3, with 
a few upregulated, a few downregulated and also some unchanged for both 
DNA/histone methyltransferases/demethylases (Figure 3.9a) and protein 
acetyltransferases/deacetylases (Figure 3.9b). We did not observe any 
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dramatic change in these epigenetic factors in the absence of STAT3, probably 
because these enzymes are so crucial for basic cell functions that their 
expression could be modulated by transcription factors only to a limited extent 
in the acute response phase.  
      Among these transcription factors, we found SIRT6, which was implicated 
in regulating cell survival and metabolism in response to stress (Preyat and 
Leo, 2013), downregulated in the absence of STAT3. As bone marrow-derived 
macrophages (BMDM) are commonly used to model the activity of cells 
comprising the innate immune system (El Kasmi et al., 2007), investigation of 
SIRT6 was performed in BMDM. To test whether SIRT6 plays a part in 
overly activated myelopoiesis in STAT3-CFF mice, the expression of SRIT6 
was examined in STAT3-deficient myeloid cells. After differentiation of 
BMDM in vitro for 7 days, the expression of SIRT6 was significantly reduced 
at mRNA level and moderately decreased at protein level in STAT3-deficient 
BMDM (Figure 3.10a, b). ChIP analysis revealed the binding of STAT3 on 
the promoter site of SIRT6 gene (Figure 3.10c), suggesting SIRT6 might be a 
downstream target of STAT3. However, the protein level of SIRT6 was not 
changed significantly in primary STAT3-/- BM granulocytes (Figure 3.10d), 
implying SIRT6 might not be involved in the STAT3-regulated granulopoiesis 
in BM. These data suggest that SIRT6 might be a potential STAT3 target and 
possibly play a role in terminally differentiated myeloid cells, but its role in 






Figure 3.9 Expression profile of selected epigenetic factors in STAT-/- BM 
immature granulocytes. BM immature granulocytes from STAT3-CFF and 
littermate STAT3-FF control mice were isolated by flow cytometry based on the 
expression of CD11b+Gr-1lo. The expression levels of a group of epigenetic factors 
including DNA/histone methyltransferases /demethylases (a), and protein 
acetyltransferases/deacetylases (b) were determined in BM immature granulocytes by 
real-time PCR. The values of expression level of each gene are standardized by 





































































































































































 Figure 3.10 STAT3 regulated the expression of Sirt6 in BMDM. 
derived macrophages (BMDM) derived from STAT3
harvest after 7 days of differentiation. SIRT
level were determined by
Stat3 protein on SIRT6 promoter site was examined by ChIP assay. Erro
represent standard deviation from three independent experiments. 
immature and mature granulocytes were isolated by flow cytometry based on the 
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4.1 Bone Marrow-Targeted Deletion of STAT3 Leads to Neutrophilia and 
aCML-Like Syndromes 
Mice with tissue-specific knockout of STAT3 in the bone marrow (STAT3-
CFF) exhibited elevated number of neutrophils in the circulating blood (Table 
3.1, Figure 3.2a), which is characterized as neutrophilia. Besides progressive 
neutrophilia, the number of basophils, eosinophils and monocytes in the blood 
were also marginally raised in STAT3-CFF mice, whereas the lymphocyte 
count was not affected significantly (Table 3.1). In consistent with this 
observation, STAT3-CFF mice also displayed phenotypes of progressive 
granulocytic hyperplasia in the bone marrow (Figure 3.6) as well as severe 
splenomegaly, the enlargement of the spleen, primarily due to massive 
neutrophil infiltration (Figure 3.1c, 3.2 b, c). These phenotypes of STAT3-
CFF mice resemble the symptoms of atypical chronic myeloid leukemia 
(aCML) in human, which is a chronic myeloproliferative disorder that features 
as sustained, peripheral blood neutrophilia without a maturation block, 
minimal basophilia and monocytosis, myeloid hyperplasia in the bone marrow 
and hepatosplenomegaly [World Health Organization (WHO) diagnostic 
criteria for aCML]. The absence of Philadelphia chromosome and its 
molecular counterpart, the BCR/ABL1 fusion gene, distinguishes aCML from 
typical chronic myeloid leukemia (CML). aCML is a rare but heterogeneous 
myeloproliferative disorder with unknown etiology and lack of effective 
treatment. The absence of characteristic and definitive molecular 
abnormalities (e.g., the BCR-ABL1 translocation in typical CML) makes the 
prognosis and accurate diagnosis of aCML rather difficult. As STAT3-CFF 
shows phenotypes alike aCML syndromes, suggesting the defective STAT3 
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signaling in the blood cells might be a potential cause for aCML or a subgroup 
of aCML. Therefore, our lab is currently working on the activity of STAT3 
signaling, i.e., the level of pStat3 protein, in the aCML patient’s white blood 
cells. If the activation/phosphorylation of Stat3 protein was impaired, 
interventions on the STAT3 signaling might help in treating these patients.  
 
4.2 Neutrophilia is Caused by Cell Autonomous Defects in STAT3-/- HSCs 
Bone Marrow (BM)-targeted deletion of STAT3 is achieved by TIE2 
promoter-driven Cre expression in STAT3 double-floxed transgenic mice. 
Since Tie2 is expressed in both BM and endothelial cells (Schnurch and Risau, 
1993), transplantation of STAT3-deficient BM into lethally irradiated wild 
type (WT) recipient mice was performed in order to ensure that such 
neutrophilic phenotype was attributed to the deficiency of STAT3 in the BM 
instead of endothelial HSC niches. By three months post BM transplantation, 
majority of the terminally differentiated peripheral blood cells were 
theoretically derived from the transplanted hematopoietic stem cells (HSCs) 
from the donor, with minority from the residual HSCs originally in the 
recipients, if any. Mice receiving STAT3-/- BM survived initially, but died of 
severe neutrophilia and related complications similar as STAT3-CFF, 
implying that the etiology for neutrophilia was inherited in the STAT3-/- BM 
cells but not in the STAT3-deficient endothelium. STAT3-/- BM was able to 
recapitulate the neutrophilic phenotype in WT mice (Figure 3.3b), suggesting 
that the neutrophilia was caused by potential cell autonomous defects in the 
STAT3-deficient BM, especially in the STAT3-/- HSCs and progenitors, from 
which all the peripheral blood cells were derived. To determine whether 
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endothelial STAT3 plays a role in regulating granulopoiesis and pathology of 
neutrophilia, a reciprocal BM transplantation of WT BM back to lethally 
irradiated STAT3-CFF mice should be performed. Unfortunately, due to the 
frailty and short life-span of STAT3-CFF mice, reciprocal BM transplantation 
is not feasible. Nonetheless, the role of endothelial STAT3 in granulopoiesis 
could be studied with mice model with endothelial-specific STAT3knockout, 
but it is not the focus of this thesis. 
       STAT3-/- BM was found able to reconstitute the peripheral blood cells in 
WT recipients, indicating that STAT3-/- HSCs had the capability of homing to 
the BM niche and differentiating. Although STAT3-/- HSCs did not exhibit 
significant abnormality in homing, the differentiation of STAT3-/- HSCs 
skewed to granulopoiesis in the WT recipients, again demonstrating a negative 
role of STAT3 in granulopoiesis (Figure 3.3c). We noted that the residual WT 
HSC-derived cells also showed preferable granulopoiesis in the presence of 
STAT3-/- blood cells, suggesting the existence of external triggers for 
granulopoiesis, most likely the secreted cytokines and chemokines from 
STAT3-deficient terminally differentiated blood cells. The extracellular 
signals may come from neutrophils themselves, or from other leukocytes, or 
even from peripheral tissues such as intestinal epithelial cells in the context of 
IBD as shown in STAT3-CFF (Welte et al., 2003). This study focuses on the 
intrinsic STAT3-dependent molecular mechanisms for the regulation of 
granulopoiesis, thus the identities and roles external players are to be 




4.3 STAT3 Modulates Lineage Specification during Early Hematopoiesis 
in the BM 
Previously, targeted deletion of STAT3 in the myeloid lineage was achieved 
by the expression of LysM-Cre in STAT3-FF mice (Takeda et al., 1999). This 
approach targeted differentiated cells but left a gap in the early hematopoiesis. 
Tie2 expression can be detected as early as embryonic day 8.5 (Schnurch and 
Risau, 1993), so that TIE2 promoter-driven Cre is able to generate STAT3-
deficient HSCs, and provides a good model to study the role of STAT3 in 
early hematopoiesis.  
      STAT3-CFF mouse was apparently normal with no severe defects 
observed when it was born, suggesting STAT3 does not play a critical role in 
fetal hematopoiesis. However, the adult hematopoiesis was greatly distorted in 
the absence of STAT3. Although the frequency of long term (LT)-HSCs was 
not changed significantly, the increased frequency of STAT3-deficient short-
term (ST)-HSCs and multipotent progenitors (MPPs) indicates an activated 
hematopoiesis with increased numbers of hematopoietic stem and progenitor 
cells (HSPCs) and subsequently differentiated progenies (Figure 3.4a,c). This 
observation suggests that STAT3 may play a suppressive role in early 
hematopoiesis by preventing the ST-HSCs from over-activation.  
      When the STAT3-/- MPPs came to the branching point of hematopoiesis 
for lineage specification, the differentiation of myeloid lineage, especially the 
granulocyte-macrophage lineage is dominant as a prominent expansion of 
granulocyte/macrophage progenitors (GMPs) occurred at the expense of both 
MEPs and CLPs, progenitors for megakaryocyte/erythrocyte and lymphoid 
lineages respectively (Figure 3.4a,c). At molecular level, the expression of the 
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B-lymphoid lineage driving factors such as E2A, EBF and PAX5 as well as 
the key megakaryocyte/erythrocyte lineage determinant GATA1 were 
significantly impaired in STAT3-deficient Lin-cKit+ HSPCs (Figure 3.5a), 
associating with the significant reduction of CLP and MEP. Surprisingly, the 
expression levels of the most classic myeloid determinate genes such as SPI1 
encoding for PU.1, and C/EBPa/b were not changed significantly in STAT3-/- 
HSPCs. These data suggest that the lineage specification is probably 
determined by a balanced expression profile of lineage determinate genes of 
all lineages. In the absence of STAT3, the differentiation potential for B-
lymphoid and megakaryocyte/erythrocyte lineages is lowered due to the 
downregulation of their lineage determinant factors, thus the potential for 
granulocyte/macrophage differentiation is uplifted as a result. Therefore, under 
normal circumstances, STAT3 may promote the specification for the lymphoid 
and megakaryocyte/erythrocyte lineages during early hematopoiesis in the BM.  
      Another explanation for the expansion of myeloid progenitors might be 
that the change in the key myeloid lineage determinate factors such as PU.1 
and CEBPα/β occurs at a specific stage during early hematopoiesis, and the 
signal was masked by the mixture of Lin-cKit+ HSPCs. In addition, it is also 
possible that some other myeloid determinate genes that might be left out in 
our current screening actually play a part in the STAT3-dependent regulation 
of myeloid specification. 
      It has been reported that STAT family members, STAT3 and STAT5 can 
be activated by erythropoietin (Epo) which is essential for the formation of 
mature red blood cells (RBCs) (Kirito et al., 1997). STAT signaling pathway 
downstream of Epo receptor is crucial for fetal liver and adult erythropoiesis, 
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and specificity for Stat3 or Stat5 is not required for Epo receptor-dependent 
signaling pathways in the regulation of erythropoiesis (Watowich et al., 2000). 
In our STAT3-CFF model, the transgenic mice were born apparently normal, 
suggesting that STAT3 is not required for fetal erythropoiesis whereby STAT5 
is sufficient to mediate Epo signaling during fetal development. However, 
during post-natal week 4 to week 6, we observed a significant reduction of 
RBC progenitors in the BM as well as a lower RBC count in the peripheral 
blood of STAT3-CFF mice (Table 3.1, Figure 3.4a). These observations 
suggest that STAT3 plays an important role in the regulation of adult 
erythropoiesis, although it might be dispensable for fetal erythropoiesis.  
      STAT3 has been shown to play critical roles for the development and 
maturation of T and B lymphocyte. STAT3 is a prerequisite for the 
differentiation of T helper 17 (Th17) cells from CD4+ T cells (Yang et al., 
2007), and plays an essential role in modulating the balance of Th17 and 
regulatory T (Treg) cells, which is critical for host immunity and the 
preservation of tolerance (Chaudhry et al., 2009; Durant et al., 2010). STAT3 
also plays an important role in B cell development in pre-pro B transition by 
contributing to the survival of IL-7-responsive progenitors (Chou et al., 2006). 
However, the role of STAT3 in MPPs for the commitment to lymphoid 
lineage during early hematopoiesis remains unknown. In this study, we found 
that the differentiation of MPP to CLP was significantly compromised in the 
absence of STAT3 (Figure 3.4c), demonstrating a critical role of STAT3 in 
lymphoid fate decision. The critical genes for B cell development function in a 
hierarchy: E2A is required for the expression of EBF, which in turn activates 
the transcription of B lineage commitment factor Pax 5 and facilitates its 
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function (Hagman and Lukin, 2006). In STAT3-/- HSPCs, the mRNA level of 
E2A was reduced by half, revealing a potential role of STAT3 in the 
transcription of E2A. We also observed a significant impairment in the 
expression of EBF and PAX5 in STAT3-/- HSPCs, which might be partially a 
consequence of compromised E2A level, yet whether STAT3 is involved in 
the regulation of EBF and PAX5 at transcriptional level is still to be elucidated. 
Our group is currently working on the detailed molecular mechanisms for 
STAT3-regulated B lineage commitment and development. 
      An active extramedullary hematopoiesis (EH) which does not occur in 
healthy adults was observed in STAT3-CFF mice (Figure 3.4d, e). It is known 
that spleen is the major site for EH under chronic hypoxia (Stutte et al., 1986). 
The STAT3-CFF mice suffers severe anemia in terms of sustained low levels 
of both RBC count and hemoglobin (Table 3.1, and data not shown). The 
insufficient oxygen transport due to anemia may render peripheral tissues 
under chronic hypoxic stress, which primarily induces EH as a compensation 
mechanism. In addition, it has been demonstrated that chronic 
infection/inflammation is an important element for EH to occur (Mirkovich et 
al., 1986). STAT3-CFF mice are highly susceptible to endotoxin and develop 
chronic enterocolitis (Welte et al., 2003), which also augments EH in the 
spleen and liver. Intriguingly, EH in STAT3-CFF spleen produced majorly 
MEPs that subsequently differentiate into RBCs as a compensation for the 
anemic phenotype, with less frequent CMPs and GMPs, displaying a different 
hematopoietic pattern from STAT3-/- BM hematopoiesis. These data suggest 
that EH that may act as an emergency hematopoiesis adopts a different 
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regulatory mechanism from BM hematopoiesis, and such extramedullary 
erythropoiesis is independent of STAT3.  
 
4.4 STAT3-IRF8 Axis Regulates the Expansion of BM Immature 
Granulocyte during Terminal Granulopoiesis 
A progressive expansion of BM granuloctyes was observed in STAT3-CFF 
mice (Figure 3.6). There was a mild expansion of neutrophils in BM and 
peripheral blood in the STAT3-FF control mice from 4 to 6 weeks of age, 
presumably due to the development and maturation of self immune system as 
it was shown that maternal separation increases neutrophil activity and innate 
immunity in C57BL/6 mice reaching adulthood (Pinheiro et al., 2011). Some 
of the 6-week-old control mice displayed moderately elevated levels of 
neutrophils in the blood and BM, implying a sign of basal level infection 
(Figure 3.2a, 3.6a). Recently, a number of studies demonstrated that the colitis 
developed in the genetically aberrant immune-compromised mice is 
transmissible to genetically and immunologically intact hosts when they are 
co-housed (Couturier-Maillard et al., 2013; Garrett et al., 2007). STAT3-CFF 
develops enterocolitis with age, thus the co-housed littermates may be also 
susceptible to colitis when STAT3-CFF develops the syndrome.  Nevertheless, 
compared with the moderate increase of neutrophils in the control mice in 
physiological and pathological conditions, the expansion of neutrophils in the 
absence of STAT3 seemed rather drastic and out of control, suggesting that 
STAT3 is required to restrain the granulopoiesis.        
95 
 
      We have already demonstrated a potential negative role of STAT3 in 
myeloid fate determination during early hematopoiesis, but enhanced 
commitment to myeloid progenitors alone may not be sufficient to result in 
such massive expansion of BM granulocytes. When cultured ex vivo, STAT3-
deficient BM cells and STAT3-deficient BM immature granulocytes display 
significantly enhanced proliferation in response to G-CSF stimulation 
(Kamezaki et al., 2005; Lee et al., 2002), implying a critical role of STAT3 in 
regulating the proliferation of granulocytes. In order to understand the 
molecular mechanism underlying the negative role of STAT3 in granulocyte 
proliferation, expression of the critical genes for myeloid cell proliferation and 
differentiation was examined in sorted primary BM immature granulocytes 
that possess greater proliferative potential than mature granulocytes. 
Surprisingly, the expression levels of the key myeloid determinate 
transcription factors PU.1, C/EBPα/β/ε and Gfi were not affected in STAT3-/- 
immature granulocytes, suggesting STAT3 regulates proliferation of 
granulocytes independent of these classic myeloid transcription factors.  
      Interferon regulatory factor 8 (IRF8), also known as interferon consensus 
sequence binding protein (ICSBP) has long been demonstrated to play a 
critical role in the regulation of granulopoiesis. Mice with a null mutation of 
IRF8 exhibited deregulated hematopoiesis manifesting the syndrome of human 
chronic myeloid leukemia, characterized by a fatal blast crisis of 
undifferentiated myeloid cells (Holtschke et al., 1996), which strongly 
suggests a role of IRF8 in the proliferation and differentiation of immature 
myeloid cells. Our data demonstrated that the expression of IRF8 was 
significantly reduced in STAT3-/- immature granulocytes (Figure 3.7), 
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associated with the overly expansion of these cells, implying that IRF8 is 
probably an effector downstream of STAT3 in the regulation of granulocyte 
proliferation. STAT3-/- immature granulocytes that were purified based on the 
expression of CD11b+Gr-1lo maintained their immature morphology (Figure 
3.6c), suggesting that downregulation of IRF8 was not due to the pre-
maturation of these immature cells. Genome-wide chromatin 
immunoprecipitation and massive parallel sequencing (ChIP-seq) has been 
performed by O’shea’s group in T cells in order to define the genome-wide 
target of Stat3, and IRF8 was found to be one of the Stat3 targets (Durant et al., 
2010). The direct binding of Stat3 on IRF8 promoter in freshly sorted BM 
immature granulocytes was confirmed by ChIP assay (Figure 3.8b), Moreover, 
luciferase reporter assay demonstrated the Stat3-mediated transactivation of 
IRF8 promoter (Figure 3.8c). These findings further support the hypothesis 
that the STAT3-IRF8 axis may play an important role in regulating the 
immature granulocytes during terminal granulopoiesis. The reduction of IRF8 
was only observed in STAT3-/- immature granulocytes, but not in STAT3-
deficient HSPCs or mature granulocytes, indicating a potential and specific 
role of STAT3-IRF8 axis in regulating granulopoiesis within a very short 
window. A recent study demonstrated that retroviral re-introduction of IRF8 
into IRF8-deficient MPPs or GMPs successfully reduced neutrophil 
production (Becker et al., 2012). Hence, re-introduction of IRF8 into STAT3-
deficient immature granulocytes is expected to rescue or attenuate the 
granulocyte hyperplasia in the BM. 
      Although IRF8 was demonstrated to play a negative role in myeloid 
proliferation and differentiation over a decade ago, very little was known 
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about the detailed molecular mechanism for IRF8-regulated granulopoiesis/ 
myelopoiesis. Researchers have been trying to identify the downstream targets 
of IRF8, and a number of mechanisms have been proposed in the recent 
studies. Firstly, IRF8 was shown to interact with PU.1, and they cooperate to 
regulate the transcription of a membrane-associated signaling Ras-GAP 
protein, NF1 (neurofibromin 1). Compromised expression of NF1 in IRF8-
deficienct myeloid cells results in cytokine hypersensitivity and 
myeloproliferation (Huang et al., 2007). Secondly, PIPN13, which encodes 
Fas-associated phosphatase 1 (Fap-1) has been identified to be an IRF8 target. 
Interaction of Fap-1 with Fas leads to Fas dephosphorylation and inhibition of 
Fas-induced apoptosis (Huang et al., 2008). In addition, IRF8 was found to 
bind directly to the promoter of Bax and Bcl-xL genes in immature myeloid 
cells, and such binding of IRF8 promotes the expression of Bax while inhibits 
the expression of Bcl-xL for the regulation of Fas-mediated apoptosis pathway 
(Hu et al., 2013; Yang et al., 2011). Hence, IRF8 deficiency may result in 
increased resistance of myeloid cells to Fas-mediated apoptosis. Thirdly, IRF8 
has been demonstrated to regulate the expression of FANCF which 
participates in the repair of corss-linked DNA. Thus IRF8 deficiency renders a 
higher risk of accumulative chromosomal abnormalities that exaggerate the 
malignancies in myeloproliferative disorders (Saberwal et al., 2009).  In sum, 
IRF8 exerts its repressive role in granulopoiesis by modulating the cytokine-
induced myeloproliferation, promoting appropriate apoptosis, protecting the 





4.5 Potential Role of STAT3 in Epigenetic Regulation of Myeloid Cells 
STAT3 has been implicated to play critical roles in the epigenetic 
reprogramming during development and in the pathogenesis of several 
diseases. (Bagnyukova et al., 2008; Gong et al., 2007; Guo et al., 2012; 
Iliopoulos et al., 2009). STAT3 was recently found to bind to multiple genes 
involving in cell proliferation and differentiation in Th17 cells, regulating both 
expression and epigenetic modifications of the promoter region of these genes 
(Durant et al., 2010). These findings demonstrate dual roles of STAT3 in 
signal transduction and activation of transcription as well as in the modulation 
of epigenetic status of target gene promoter.  The mechanisms for STAT3-
dependent epigenetic regulation of genome have been proposed by either 
directly regulating the transcription of histone/DNA modifying enzymes, and 
therefore contributing to the global reprogramming process,  or by associating 
with series of enzymes to modulate the epigenetic codes such as to adjust the 
expression level of the STAT3 downstream gene(s) (Guo et al., 2012; 
Nguyen-Jackson et al., 2010). Hence, in our study, a possible role of STAT3 
in the epigenetic regulation of granulopoiesis was investigated by searching 
for STAT3-regulated epigenetic factors that may play a role in granulopoiesis.  
      Since STAT3 deletion leads to massive expansion of BM immature 
granulocytes, expression levels of a set of epigenetic factors in STAT3-/- BM 
immature granulocytes were examined. The expression levels of most tested 
epigenetic factors changed only marginally in STAT3-deficient granulocytes. 
As for both DNA/histone methyltransferases/demethylases and protein 
acetyltransferases/deacetylases, their expression levels in STAT3-deficient 
cells were altered only less than 2-fold up- or down-regulation with a couple 
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unchanged, compared with the control (Figure 3.9). No dramatic change in the 
expression of these epigenetic factors was observed as to the extent of 
transcription factor IRF8. It is probably because these enzymes are critical for 
basic cell functions and their expression might not be modulated to an extreme 
level in the acute response phase by transcription factors such as STAT3. 
Whether the relatively moderate changes in the expression of epigenetic 
factors have great impact on cell survival and function remains unclear, and 
requires further investigation. 
      Among these epigenetic factors in which the expression level was altered 
in STAT3-deficient BM granulocytes, we picked up SIRT6 for further 
investigation. SIRT6 is a member of sirtuin family which are known as histone 
lysine deacetylases. It is reported to play an important role in maintaining cell 
homeostasis by regulating energy status and stress resistance (Finkel et al., 
2009).  SIRT6-knockout mice appear normal at birth but have a shortened 
lifespan and an aging-like phenotype (Mostoslavsky et al., 2006), which share 
some similar phenotypes with STAT3-CFF mice. Thus potential relationship 
between STAT3 and SIRT6 is of great interest. Using cultured bone marrow-
derived macrophages (BMDM) as a representative for innate immune cells, 
we found SIRT6 mRNA level was significantly reduced in the absence of 
STAT3, accompanied with a moderate decrease in its protein level. Moreover, 
direct binding of Stat3 protein to SIRT6 promoter was detected in BMDM by 
ChIP assay (Figure 3.10 a-c), implying that SIRT6 might be a potential 
downstream target gene of STAT3 in terminally differentiated myeloid cells. 
However, the impact of this potential STAT3-SIRT6 axis on the function of 
BMDM is yet to be elucidated. The level of Sirt6 protein, however, was not 
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changed in freshly sorted primary STAT3-/- BM granulocytes, although its 
mRNA level was moderately downregulated, suggesting the potential 
regulatory role of STAT3 in SIRT6 transcription observed in BMDM culture 
may not apply to BM granulocytes in vivo.  
 
4.6 STAT3 Regulates Granulopoiesis and Neutrophilia at Multiple Levels 
Our study has demonstrated that the progressive neutrophilia in transgenic 
mice with conditional STAT3 deletion in the BM was attributed to the cell 
autonomous defects residing in STAT3-/- BM (Figure 3.3). By studying the 
pathogenesis of neutrophilia in STAT3-CFF mice, novel roles of STAT3 in 
regulating granulopoiesis have been revealed. 
      During early hematopoiesis, STAT3 is likely to promote the commitment 
of HSCs and MPPs towards lymphoid lineage and megakaryocyte/erythrocyte 
lineage by promoting the transcription of their respective lineage determinate 
genes. Thus, in the absence of STAT3, the balanced expression profile of the 
lineage-driving factors of each lineage is disrupted. The impaired expression 
of lymphoid and megakaryocyte/erythrocyte determinate factors may result in 
an uplifted potential for the differentiation towards the myeloid lineage, giving 
rise to more myeloid progenitors and subsequent myeloid cells (Figure 3.4, 
3.5). In addition, there might be other factors and mechanisms involved in the 
STAT3-regulated lineage specification, and we will do further screening in 
future. 
      Once committed to the myeloid lineage, cells undergo further 
differentiation and maturation in the BM and form functional neutrophil 
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granulocytes, and the process is termed ‘terminal granulopoiesis’. We 
observed a reduced expression of IRF8 in STAT3-/- BM immature 
granulocytes, accompanying by a drastic expansion of these cells. This 
suggests IRF8 as a potential downstream target of STAT3 in regulating the 
neutrophil count during terminal granulopoiesis. Direct binding of STAT3 to 
the IRF8 promoter region in BM immature granulocytes was confirmed by 
ChIP analysis (Figure 7, 8). Therefore, a STAT3-IRF8 axis might be critical 
for maintaining the neutrophil homeostasis in the BM during terminal 
granulopoiesis, and deletion of STAT3 leads to tremendous expansion of BM 
granulocytes resulting in neutrophilia.  
      In addition to the developmental defects in STAT3-deficient BM, the 
chronic inflammatory bowel disease (IBD) developed in late life of STAT3-
CFF mice induces emergency granulopoiesis (Panopoulos et al., 2006; Welte 
et al., 2003), and exacerbate neutrophilia. We did not observe obvious lesions 
in the intestine and colon in 3-week-old STAT3-CFF mice (data not shown), 
suggesting that IBD contributes to neutrophilia at a relatively late stage of 
disease pathogenesis. As STAT3 has been shown to play a critical role in 
immune tolerance at periphery (Cheng et al., 2003), it is not surprising that 
STAT3 is involved in the suppression of gut inflammation and in the 
maintenance of peripheral neutrophil homeostasis. 
      It is noteworthy that EH in the STAT3-CFF spleen and liver also produced 
certain amount of granulocyte/macrophage progenitors and subsequently 
neutrophils (Figure 3.4). Although committing to the granulocyte/macrophage 
lineage to a much less extent than to the erythrocytes, EH in STAT3-CFF 
actually further exaggerated neutrophilia. Moreover, the excessive production 
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of TNF-α and other inflammatory cytokines in STAT3-CFF mice (Welte et al., 
2003) may also accelerate the growth and maturation of myeloid progenitors.  
 
4.7 Conclusion 
Mice with targeted deletion of STAT3 in the BM exhibited phenotype of 
severe neutrophilia and aCML-like syndromes, resulting from the cell 
autonomous defects in STAT3-deficient bone marrow cells. STAT3-/- HSPCs 
preferably differentiated towards myeloid progenitors CMP and GMP at the 
expense of MEP and CLP, the progenitors for megakaryocyte/erythrocyte and 
lymphoid lineages respectively, corresponding to the impaired expression of 
cell fate determinate genes of these lineages. The data suggest that STAT3 
may play an important role in promoting lineage specification to 
megakaryocyte/erythrocyte and lymphoid lineages during early hematopoiesis. 
In addition, expression of IRF8, a suppressor of granulopoiesis, was 
downregulated in overly expanded STAT3-/- BM immature granulocytes, and 
it is a potential STAT3 downstream target revealed by ChIP analysis, implying 
a STAT3-IRF8 axis as a potential regulatory mechanism in neutrophil 
homeostasis in the BM. Moreover, STAT3 may play a part in the epigenetic 
regulation of myeloid cells through the regulation of certain epigenetic factors. 
In conclusion, STAT3 regulates granulopoiesis and neutrophilia at multiple 
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Table S.1 Real-time PCR primers for the screening of epigenetic factors 
gene primer sequences 
Aanat 
Forward TGA GCG GGA AGC CTT TAT CTC 
Reverse CTC CTG AGT AAG TCT CTC CTT GT 
Ash2I 
Forward TGA CAC CTT TGG AAT AGA CAC G 
Reverse AAG GCA CTA AGG CAC ATT TCT T 
Bhmt 
Forward TTA GAA CGC TTA AAT GCC GGA G 
Reverse GAT GAA GCT GAC GAA CTG CCT 
Crat 
Forward GCT GCC AGA ACC GTG GTA AA 
Reverse CCT TGA GGT AAT AGT CCA GGG A 
Dlat 
Forward TCC CTC CGC ATC AGA AGG TT 
Reverse CCA ACT GGA ACA TCT CTG GTC 
Dnmt1 
Forward ATC CTG TGA AAG AGA ACC CTG T 
Reverse CCG ATG CGA TAG GGC TCT G 
Dnmt3a 
Forward GAG GGA ACT GAG ACC CCA C 
Reverse CTG GAA GGT GAG TCT TGG CA 
Dnmt3b 
Forward GTT AAT GGG AAC TTC AGT GAC CA 
Reverse CTG CGT GTA ATT CAG AAG GCT 
Ehmt1 
Forward CTG ATG CGC CCA TCC AAC A 
Reverse GGC ATT CCA TGA AGT TAC CCG 
Ep300 
Forward TTC AGC CAA GCG GCC TAA A 
Reverse CGC CAC CAT TGG TTA GTC CC 
Ezh2 
Forward TGC CTC CTG AAT GTA CTC CAA 
Reverse AGG GAT GTA GGA AGC AGT CAT AC 
Ftsjd1 Forward AGC TTT TCC TAC CGT AAG CCA 
Reverse CTT CAC TTC GTT CAG GGA GTT C 
Gcat 
Forward GGA CAG CGA ACT GGA AGG G 
Reverse AGT TAT TGG CAC AGA AGT TGA GG 
Gnpnat1 
Forward ATG AAA CCC GAT GAA ACT CCC 
Reverse GCC TCA AAA CCA AGC CTT CTC 
Hdac1 
Forward TCT ACC GCC CTC ACA AAG C 
Reverse ACA GAA CTC AAA CAA GCC ATC A 
Hdac2 
Forward AAG GAG GTC GTA GGA ATG TTG C 
Reverse GGG GTC TGT TTT CTC ACC ACT AT 
Hdac5 
Forward AGC ACC GAG GTA AAG CTG AG 
Reverse GCT GTG GGA GGG AAT GGT T 
Hdac6 
Forward ACA ACC CAG TAC ATG AAT GAA GG 
Reverse CCC CAT GAG TGC ATC TAC CA 
Hdac8 
Forward ATC TCC AGA AGG TCA GCC AAG 
Reverse ACA TTC CGT CAA TCA GGC ATT 
Hdac9 Forward GCG GTC CAG GTT AAA ACA GAA 




Forward ACG ACG TGA ACC GCT TCA T 
Reverse GCC GTG TAG AGC TGC ACA G 
Jmjd1a Forward GAA CTG CCA ACA GGG TGC T 
Reverse TGC TCT GAC AGA ATG CAC AAT 
Kat5 Forward TCC CGG TCC AGA TCA CAC TC 
Reverse ACC TTC CGT TTC GTT GAG CG 
Mak10 
Forward AGC TAC TGT AGA CGA CGA TGC 
Reverse AAC TTC AGC TCT CGA CAA GCA 
Myst1 
Forward ACG AGG CGA TCA CCA AAG TG 
Reverse AAG CGG TAG CTC TTC TCG AAC 
Myst2 
Forward ATG CCG CGA AGG AAG AGA AAT 
Reverse TCT TGG GAA CTC TGG CTT AGC 
Nat1 
Forward TTG TAA GCA CAT CGT TCT GTT CC 
Reverse AAT GCC AAA TGC GGT TTT CAG 
Nat2 
Forward ACA CTC CAG CCA ATA AGT ACA GC 
Reverse GGT AGG AAC GTC CAA ACC CA 
Nat3 
Forward TGG AAC TGA GCT TAG AGG ACA C 
Reverse CTA ACA TTG TGG TCT CAA ACC CT 
Nat6 Forward TGC CCG CTT ATC ACG GGT A 
Reverse TGA GGT GTA GCC GTC GGA AA 
Nat10 
Forward GCG GCA GAG GTC TCT TTT TGT 
Reverse GTG ACT GCT AAA TCC CAG CTC 
Nat13 
Forward TAG GAT GCC TTG CAC CTT ACC 
Reverse GTC AAT CGC TGA CTC ATT GCT 
Ndst2 
Forward TAG TCG CTT TCG TTA TAG CAC TG 
Reverse GCT CCA GGC ATC TAA GTT CAC A 
Ndst3 
Forward TGC TTG CCA CCT TTT GTA TGG 
Reverse AGC ATC GGA AAT CAT TGT CCT C 
Ndst4 
Forward ACT TTT TGC TTG GTG AGC ATC C 
Reverse CCG ATA AGG GAG GTC TTT GAT GT 
Nsd1 
Forward CAA CAG CAC TTG CTA TGA AAC AG 
Reverse GCA TCG TCC ACA CCA GTA AAA 
Prmt3 
Forward CAG AGC ACC AAA ACA CAC TGG 
Reverse TCA GGG TCA CAA TGA GGG AAC 
Prmt6 
Forward ATG TCG CTG AGC AAG AAA AGA 
Reverse CGG AGT AGC ACT CGT AGT ACA G 
Prmt7 
Forward GCC AGG TCA TCC TAT GCC G 
Reverse GCC AAT GTC AAG AAC CAA GGC 
Setd7 
Forward GGC TGA TCT TCA AGG GAC AGT 
Reverse TTT TCT CCC GTC ATC TCT CCA 
Setd8 
Forward CAG GGG TGT GAT CGC TAC C 







Forward GCT GAC GAC TTC GAC GAC G 
Reverse TCG GTC AAC AGG AGG TTG TCT 
Sirt2 
Forward GCC TGG GTT CCC AAA AGG AG 
Reverse GAG CGG AAG TCA GGG ATA CC 
Sirt4 
Forward CAG CAC ATT GAT TTC GTC CGC 
Reverse GTG CAA AGC GTC CAC GTT C 
Sirt6 Forward ATG TCG GTG AAT TAT GCA GCA 
Reverse GCT GGA GGA CTG CCA CAT TA 
Sirt7 
Forward GGT CCA GCT TGA AGG TAC TAA AG 
Reverse TGA GGA GTT GCA TGA CAT CAT C 
Suv39h1 
Forward GCA GTG TGT GCT GTA AAT CTT CT 
Reverse ATA CCC ACG CCA CTT AAC CAG 
Suv39h2 
Forward ATC TAC GAA TGC AAC TCA AGG TG 
Reverse CCA CAG CCA TTG CTA GTT CTA A 
Suv420h1 
Forward CGG CTG CTT CCA ACT CTA CC 
Reverse AGT GAT TCC GCA GTC TGA TCT 
Suv420h2 
Forward GAC CAA AGC CCC TAG ACA AGT 
Reverse GCA GCA CAG AAT GGG TCA G 
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Table S.2 Epigenetic factors: gene names and functions 
Gene Function 
Aanat arylalkylamine N-acetyltransferase 
Ash2l histone methyltransferase complex subunit 
Bhmt betaine-homocysteine methyltransferase 
Crat carnitine O-acetyltransferase 
Dlat dihydrolipoamide S-acetyltransferase 
Dnmt1 DNA methyltransferase (cytosine-5)  
Dnmt3a DNA methyltransferase (cytosine-5)  
Dnmt3b DNA methyltransferase (cytosine-5)  
Ehmt1 histone-lysine n-methyltransferase 
Ep300 histone acetyltransferase 
Ezh2 histone-lysine N-methyltransferase 
Ftsjd1 FtsJ methyltransferase domain containing 1 
Gcat glycine C-acetyltransferase 
Gnpnat1 glucosamine-phosphate N-acetyltransferase 1 
Hdac1 histone deacetylase 
Hdac2 histone deacetylase 
Hdac5 histone deacetylase 
Hdac6 histone deacetylase 
Hdac8 histone deacetylase 
Hdac9 histone deacetylase 
Jhdm1d 
jumonji C domain-containing histone demethylase 1 
homolog D  
Jmjd1a jumonji C domain-containing histone demethylation protein 
Kat5 lysine (K)-specific acetyltransferase 
Mak10 NatC N-acetyltransferase complex subunit 
Myst1 K(lysine) acetyltransferase 8 
Myst2 K(lysine) acetyltransferase 7 
Nat1 gcn5-like (arylamine) n-acetyltransferase 
Nat2 gcn5-like (arylamine) n-acetyltransferase 
Nat3 gcn5-like (arylamine) n-acetyltransferase 
Nat6 gcn5-like (arylamine) n-acetyltransferase 
Nat10 gcn5-like (arylamine) n-acetyltransferase 




Nsd1 histone-lysine N-methyltransferase 
Nsd2 histone-lysine N-methyltransferase 
Prmt3 protein arginine methyltransferase  
Prmt6 protein arginine methyltransferase  
Prmt7 protein arginine methyltransferase  
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Setd7 lysine methyltransferase) 7 
Setd8 SET domain containing (lysine methyltransferase) 8 
Sirt1 NAD-dependent deacetylase sirtuin 
Sirt2 NAD-dependent deacetylase sirtuin 
Sirt4 NAD-dependent deacetylase sirtuin 
Sirt6 NAD-dependent deacetylase sirtuin 
Sirt7 NAD-dependent deacetylase sirtuin 
Suv39h1 histone-lysine N-methyltransferase 
Suv39h2 histone H3-K9 (lysine-N) methyltransferase 2 
Suv420h1 histone-lysine N-methyltransferase 
Suv420h2 histone-lysine N-methyltransferase 
 
